|
G |
Cdh1 |
cadherin 1 |
increases expression |
ISO |
atorvastatin co-treated with N-nitrosodiethylamine increases expression of Cdh1 mRNA in liver |
RGD |
PMID:25319454 |
RGD:152995431 |
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
atorvastatin inhibits the reaction [alcohol increases expression of HSPA5 protein in cardiomyocytes] |
RGD |
PMID:30160187 |
RGD:401827866 |
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
increases expression decreases expression |
ISO |
Atorvastatin increases expression of NR1H3 mRNA in mononuclear cells Atorvastatin decreases expression of NR1H3 protein in macrophages |
RGD |
PMID:16252156 PMID:17644777 |
RGD:401827902, RGD:401827903 |
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
decreases expression |
ISO |
atorvastatin co-treated with N-nitrosodiethylamine decreases expression of Slco1b2 mRNA in liver |
RGD |
PMID:25319454 |
RGD:152995431 |
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
decreases expression |
ISO |
atorvastatin decreases expression of SREBF1 protein in cardiomyocytes |
RGD |
PMID:30160187 |
RGD:401827866 |
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions decreases activity |
ISO |
cerivastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; cerivastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] cerivastatin results in decreased activity of ABCB11 protein |
CTD |
PMID:15901796 PMID:24014644 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
affects export |
ISO |
ABCB1 protein affects the export of cerivastatin |
CTD |
PMID:15901800 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
affects export |
ISO |
ABCC2 protein affects the export of cerivastatin |
CTD |
PMID:15901800 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
affects export |
ISO |
ABCG2 protein affects the export of cerivastatin |
CTD |
PMID:15901800 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
increases secretion |
ISO |
cerivastatin results in increased secretion of BMP2 protein |
CTD |
PMID:16470222 |
|
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions |
ISO |
cerivastatin results in increased activity of CASP3 protein geranylgeranyl pyrophosphate inhibits the reaction [cerivastatin results in increased activity of CASP3 protein]; Mevalonic Acid inhibits the reaction [cerivastatin results in increased activity of CASP3 protein] |
CTD |
PMID:15705602 PMID:16470222 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases activity |
ISO |
cerivastatin results in increased activity of CASP8 protein |
CTD |
PMID:15705602 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases activity |
ISO |
cerivastatin results in increased activity of CASP9 protein |
CTD |
PMID:15705602 PMID:16470222 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions decreases expression |
ISO |
cerivastatin inhibits the reaction [TNF results in increased expression of CCL2 mRNA]; cerivastatin results in decreased expression of and results in decreased secretion of CCL2 protein; Mevalonic Acid inhibits the reaction [cerivastatin inhibits the reaction [TNF results in increased expression of CCL2 mRNA]] cerivastatin results in decreased expression of CCL2 mRNA |
CTD |
PMID:12117737 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
increases expression |
ISO |
cerivastatin results in increased expression of CYP2B6 mRNA |
CTD |
PMID:15802384 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
affects response to substance increases metabolic processing |
ISO |
CYP2C8 gene mutant form affects the susceptibility to cerivastatin CYP2C8 protein results in increased metabolism of cerivastatin |
CTD |
PMID:12464242 PMID:15365880 PMID:15716363 |
|
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases metabolic processing |
ISO |
CYP3A4 protein results in increased metabolism of cerivastatin |
CTD |
PMID:15365880 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Diablo |
diablo, IAP-binding mitochondrial protein |
increases localization |
ISO |
cerivastatin results in increased localization of DIABLO protein |
CTD |
PMID:15705602 |
|
NCBI chr12:33,055,784...33,070,401
Ensembl chr12:33,055,263...33,070,387
|
|
G |
Entpd1 |
ectonucleoside triphosphate diphosphohydrolase 1 |
multiple interactions |
ISO |
cerivastatin inhibits the reaction [F2 protein results in decreased expression of ENTPD1 protein] |
CTD |
PMID:12067895 |
|
NCBI chr 1:239,425,515...239,552,323
Ensembl chr 1:239,425,430...239,552,317
|
|
G |
F2 |
coagulation factor II, thrombin |
multiple interactions |
ISO |
cerivastatin inhibits the reaction [F2 protein results in decreased expression of ENTPD1 protein] |
CTD |
PMID:12067895 |
|
NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
decreases expression |
EXP |
cerivastatin results in decreased expression of FGF2 mRNA; cerivastatin results in decreased expression of FGF2 protein |
CTD |
PMID:11479256 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
cerivastatin inhibits the reaction [TNF results in increased expression of ICAM1] |
CTD |
PMID:12615677 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression |
EXP |
cerivastatin results in decreased expression of IL1B |
CTD |
PMID:12878482 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions decreases expression |
ISO EXP |
cerivastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]; cerivastatin results in decreased expression of and results in decreased secretion of IL6 protein; Mevalonic Acid inhibits the reaction [cerivastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]] cerivastatin results in decreased expression of IL6 cerivastatin results in decreased expression of IL6 mRNA |
CTD |
PMID:11479256 PMID:12117737 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itgal |
integrin subunit alpha L |
multiple interactions |
ISO |
cerivastatin inhibits the reaction [TNF results in increased expression of ITGAL] |
CTD |
PMID:12615677 |
|
NCBI chr 1:181,918,183...181,955,735
Ensembl chr 1:181,918,183...181,955,732
|
|
G |
Itgb2 |
integrin subunit beta 2 |
multiple interactions |
ISO |
cerivastatin inhibits the reaction [TNF results in increased expression of ITGB2] |
CTD |
PMID:12615677 |
|
NCBI chr20:11,061,394...11,097,656
Ensembl chr20:11,061,430...11,097,600
|
|
G |
Mb |
myoglobin |
increases secretion |
EXP |
cerivastatin results in increased secretion of MB protein |
CTD |
PMID:19628585 |
|
NCBI chr 7:108,759,903...108,767,134
Ensembl chr 7:108,759,904...108,767,383
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity |
ISO |
cerivastatin results in increased activity of NR1I2 protein |
CTD |
PMID:15802384 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
decreases activity increases activity |
ISO EXP |
cerivastatin results in decreased activity of NR1I3 protein alternative form cerivastatin results in increased activity of NR1I3 protein |
CTD |
PMID:15802384 PMID:21778469 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
cerivastatin promotes the reaction [Bezafibrate results in increased activity of [PPARA protein binds to RXRA protein]]; Cholesterol inhibits the reaction [cerivastatin promotes the reaction [Bezafibrate results in increased activity of [PPARA protein binds to RXRA protein]]]; Farnesol inhibits the reaction [cerivastatin promotes the reaction [Bezafibrate results in increased activity of [PPARA protein binds to RXRA protein]]]; geranylgeraniol inhibits the reaction [cerivastatin promotes the reaction [Bezafibrate results in increased activity of [PPARA protein binds to RXRA protein]]]; Mevalonic Acid inhibits the reaction [cerivastatin promotes the reaction [Bezafibrate results in increased activity of [PPARA protein binds to RXRA protein]]]; SREBF1 protein inhibits the reaction [cerivastatin promotes the reaction [Bezafibrate results in increased activity of [PPARA protein binds to RXRA protein]]] |
CTD |
PMID:11779144 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Rab4a |
RAB4A, member RAS oncogene family |
decreases prenylation affects expression |
EXP |
cerivastatin results in decreased prenylation of RAB4 protein cerivastatin affects the expression of RAB4A protein |
CTD |
PMID:16239165 |
|
NCBI chr19:51,795,613...51,822,706
Ensembl chr19:51,795,613...51,822,703
|
|
G |
Rap1a |
RAP1A, member of RAS oncogene family |
multiple interactions decreases geranoylation |
ISO |
Mevalonic Acid inhibits the reaction [cerivastatin results in decreased geranoylation of RAP1A protein] |
CTD |
PMID:25578243 |
|
NCBI chr 2:193,208,631...193,286,513
Ensembl chr 2:193,208,635...193,286,501
|
|
G |
Rhoa |
ras homolog family member A |
decreases localization multiple interactions |
ISO |
cerivastatin results in decreased localization of RHOA protein cerivastatin results in increased localization of and results in decreased prenylation of RHOA protein |
CTD |
PMID:15705602 PMID:16470222 |
|
NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Rxra |
retinoid X receptor alpha |
multiple interactions |
ISO |
cerivastatin promotes the reaction [Bezafibrate results in increased activity of [PPARA protein binds to RXRA protein]]; Cholesterol inhibits the reaction [cerivastatin promotes the reaction [Bezafibrate results in increased activity of [PPARA protein binds to RXRA protein]]]; Farnesol inhibits the reaction [cerivastatin promotes the reaction [Bezafibrate results in increased activity of [PPARA protein binds to RXRA protein]]]; geranylgeraniol inhibits the reaction [cerivastatin promotes the reaction [Bezafibrate results in increased activity of [PPARA protein binds to RXRA protein]]]; Mevalonic Acid inhibits the reaction [cerivastatin promotes the reaction [Bezafibrate results in increased activity of [PPARA protein binds to RXRA protein]]]; SREBF1 protein inhibits the reaction [cerivastatin promotes the reaction [Bezafibrate results in increased activity of [PPARA protein binds to RXRA protein]]] |
CTD |
PMID:11779144 |
|
NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
ISO |
SREBF1 protein inhibits the reaction [cerivastatin promotes the reaction [Bezafibrate results in increased activity of [PPARA protein binds to RXRA protein]]] |
CTD |
PMID:11779144 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
cerivastatin inhibits the reaction [TNF results in increased expression of CCL2 mRNA]; cerivastatin inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]; cerivastatin inhibits the reaction [TNF results in increased expression of ICAM1]; cerivastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]; cerivastatin inhibits the reaction [TNF results in increased expression of ITGAL]; cerivastatin inhibits the reaction [TNF results in increased expression of ITGB2]; Mevalonic Acid inhibits the reaction [cerivastatin inhibits the reaction [TNF results in increased expression of CCL2 mRNA]]; Mevalonic Acid inhibits the reaction [cerivastatin inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]]; Mevalonic Acid inhibits the reaction [cerivastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]] |
CTD |
PMID:12117737 PMID:12615677 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnni2 |
troponin I2, fast skeletal type |
increases secretion |
EXP |
cerivastatin results in increased secretion of TNNI2 protein |
CTD |
PMID:19628585 |
|
NCBI chr 1:197,595,012...197,597,554
Ensembl chr 1:197,594,813...197,597,560
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions |
ISO |
[ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to Fluvastatin; [APOB gene SNP co-treated with APOE gene SNP co-treated with HMGCR gene SNP co-treated with LDLR gene SNP co-treated with PCSK9 gene SNP co-treated with ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to Fluvastatin |
CTD |
PMID:19773416 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases activity multiple interactions |
ISO |
fluvastatin results in decreased activity of ABCB11 protein fluvastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid] |
CTD |
PMID:15901796 PMID:20829430 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
affects transport multiple interactions |
EXP ISO |
ABCC2 protein affects the transport of fluvastatin ABCC2 protein binds to and results in increased uptake of fluvastatin analog; fluvastatin analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein]; fluvastatin promotes the reaction [ABCC2 protein results in increased export of 5(6)-carboxy-2',7'-dichlorofluorescein] |
CTD |
PMID:16026004 PMID:23562342 PMID:24909372 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
Fluvastatin inhibits the reaction [bisphenol A results in increased phosphorylation of AKT1 protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in increased phosphorylation of AKT1 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in increased phosphorylation of AKT1 protein]] |
CTD |
PMID:35465754 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Apob |
apolipoprotein B |
multiple interactions |
ISO |
[APOB gene SNP co-treated with APOE gene SNP co-treated with HMGCR gene SNP co-treated with LDLR gene SNP co-treated with PCSK9 gene SNP co-treated with ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to fluvastatin; fluvastatin promotes the reaction [[Valsartan co-treated with benazepril] results in decreased expression of APOB protein] |
CTD |
PMID:19773416 PMID:20671225 |
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Apoe |
apolipoprotein E |
multiple interactions increases expression |
ISO |
[APOB gene SNP co-treated with APOE gene SNP co-treated with HMGCR gene SNP co-treated with LDLR gene SNP co-treated with PCSK9 gene SNP co-treated with ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to fluvastatin fluvastatin results in increased expression of APOE protein |
CTD |
PMID:8017468 PMID:19773416 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Arhgap29 |
Rho GTPase activating protein 29 |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of ARHGAP29 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 2:210,060,036...210,132,572
Ensembl chr 2:210,071,199...210,132,028
|
|
G |
Arhgef12 |
Rho guanine nucleotide exchange factor 12 |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of ARHGEF12 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 8:43,350,070...43,475,404
Ensembl chr 8:43,353,799...43,476,366
|
|
G |
Arhgef3 |
Rho guanine nucleotide exchange factor 3 |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of ARHGEF3 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr16:2,301,573...2,581,951
Ensembl chr16:2,300,138...2,581,945
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
Fluvastatin inhibits the reaction [bisphenol A results in increased expression of BAX protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in increased expression of BAX protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in increased expression of BAX protein]] |
CTD |
PMID:35465754 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcap29 |
B-cell receptor-associated protein 29 |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of BCAP29 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 6:48,182,702...48,222,698
Ensembl chr 6:48,182,706...48,222,720
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of BCL2 protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of BCL2 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of BCL2 protein]] |
CTD |
PMID:35465754 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of BCL2L11 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Becn1 |
beclin 1 |
multiple interactions |
EXP |
Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of BECN1 protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of BECN1 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of BECN1 protein]] |
CTD |
PMID:35465754 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Bhlhe40 |
basic helix-loop-helix family, member e40 |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of BHLHE40 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 4:141,618,453...141,624,154
Ensembl chr 4:141,618,476...141,624,774
|
|
G |
Bub1 |
BUB1 mitotic checkpoint serine/threonine kinase |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of BUB1 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 3:115,020,254...115,051,650
Ensembl chr 3:115,020,254...115,051,650
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of CASP1 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO EXP |
fluvastatin results in increased cleavage of and results in increased activity of CASP3 protein; Mevalonic Acid inhibits the reaction [fluvastatin results in increased cleavage of and results in increased activity of CASP3 protein] Fluvastatin inhibits the reaction [bisphenol A results in increased expression of CASP3 protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in increased expression of CASP3 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in increased expression of CASP3 protein]] |
CTD |
PMID:24964743 PMID:35465754 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases activity multiple interactions |
ISO |
fluvastatin results in increased activity of CASP8 protein Mevalonic Acid inhibits the reaction [fluvastatin results in increased activity of CASP8 protein] |
CTD |
PMID:24964743 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Cat |
catalase |
increases expression multiple interactions |
ISO EXP |
fluvastatin results in increased expression of CAT protein Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of CAT protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of CAT protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of CAT protein]] |
CTD |
PMID:24964743 PMID:35465754 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
EXP |
fluvastatin inhibits the reaction [Puromycin Aminonucleoside results in increased expression of CCL2 mRNA] |
CTD |
PMID:16452496 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Cdk2ap2 |
cyclin-dependent kinase 2 associated protein 2 |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of CDK2AP2 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 1:201,391,056...201,393,137
Ensembl chr 1:201,391,466...201,393,137
|
|
G |
Cks2 |
CDC28 protein kinase regulatory subunit 2 |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of CKS2 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr17:13,570,611...13,575,770
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
increases expression |
ISO |
fluvastatin results in increased expression of CYP2B6 mRNA |
CTD |
PMID:15802384 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity multiple interactions |
ISO |
Fluvastatin results in decreased activity of CYP3A4 protein [Fluvastatin co-treated with NR1I2 protein] results in increased expression of CYP3A4 mRNA; Fluvastatin inhibits the reaction [CYP3A4 protein affects the metabolism of Midazolam] |
CTD |
PMID:16029222 PMID:24204015 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Ddb2 |
damage specific DNA binding protein 2 |
decreases expression multiple interactions |
ISO |
fluvastatin results in decreased expression of DDB2 mRNA; fluvastatin results in decreased expression of DDB2 protein [fluvastatin results in decreased expression of DDB2] which results in increased expression of SOD2 mRNA; Mevalonic Acid inhibits the reaction [fluvastatin results in decreased expression of DDB2 mRNA]; Mevalonic Acid inhibits the reaction [fluvastatin results in decreased expression of DDB2 protein] |
CTD |
PMID:24964743 |
|
NCBI chr 3:77,185,114...77,207,650
Ensembl chr 3:77,185,109...77,207,631
|
|
G |
Ednra |
endothelin receptor type A |
decreases expression |
EXP |
fluvastatin results in decreased expression of EDNRA mRNA |
CTD |
PMID:28951255 |
|
NCBI chr19:30,233,540...30,303,727
Ensembl chr19:30,233,571...30,297,049
|
|
G |
Emp3 |
epithelial membrane protein 3 |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of EMP3 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 1:96,388,651...96,391,946
Ensembl chr 1:96,388,652...96,391,988
|
|
G |
Ercc5 |
ERCC excision repair 5, endonuclease |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of ERCC5 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 9:46,309,477...46,354,478
Ensembl chr 9:46,309,389...46,354,472
|
|
G |
Erg |
ETS transcription factor ERG |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of ERG mRNA |
CTD |
PMID:16996129 |
|
NCBI chr11:34,678,614...34,900,951
Ensembl chr11:34,678,618...34,845,871
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions decreases expression |
ISO |
Fluvastatin inhibits the reaction [Lipopolysaccharides promotes the reaction [[REL protein binds to RELA protein] which binds to F3 promoter]]; geranylgeraniol inhibits the reaction [Fluvastatin results in decreased expression of F3 protein]; Mevalonic Acid inhibits the reaction [Fluvastatin results in decreased expression of F3 mRNA]; Mevalonic Acid inhibits the reaction [Fluvastatin results in decreased expression of F3 protein] Fluvastatin results in decreased expression of F3 mRNA; Fluvastatin results in decreased expression of F3 protein |
CTD |
PMID:9081680 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Fdft1 |
farnesyl diphosphate farnesyl transferase 1 |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of FDFT1 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287
|
|
G |
Fnta |
farnesyltransferase, CAAX box, subunit alpha |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of FNTA mRNA |
CTD |
PMID:16996129 |
|
NCBI chr16:66,065,131...66,083,460
Ensembl chr16:66,065,132...66,083,460
|
|
G |
Foxo1 |
forkhead box O1 |
decreases phosphorylation |
ISO |
Fluvastatin results in decreased phosphorylation of FOXO1 protein |
CTD |
PMID:33034787 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions |
EXP |
Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of FSHB protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of FSHB protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of FSHB protein]] |
CTD |
PMID:35465754 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
ISO |
[Fluvastatin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA |
CTD |
PMID:24204015 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
multiple interactions |
EXP |
Fluvastatin inhibits the reaction [bisphenol A results in decreased activity of G6PD protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased activity of G6PD protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased activity of G6PD protein]] |
CTD |
PMID:35465754 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of GADD45B mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP |
Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of GSR protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of GSR protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of GSR protein]] |
CTD |
PMID:35465754 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions decreases activity |
ISO |
[APOB gene SNP co-treated with APOE gene SNP co-treated with HMGCR gene SNP co-treated with LDLR gene SNP co-treated with PCSK9 gene SNP co-treated with ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to fluvastatin fluvastatin results in decreased activity of HMGCR protein |
CTD |
PMID:8593127 PMID:19773416 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of HMOX1 protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of HMOX1 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of HMOX1 protein]] |
CTD |
PMID:35465754 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hsd17b1 |
hydroxysteroid (17-beta) dehydrogenase 1 |
multiple interactions |
EXP |
Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of HSD17B1 protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of HSD17B1 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of HSD17B1 protein]] |
CTD |
PMID:35465754 |
|
NCBI chr10:86,009,728...86,011,928
Ensembl chr10:86,009,728...86,011,927
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions |
EXP |
Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of HSD3B1 protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of HSD3B1 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of HSD3B1 protein]] |
CTD |
PMID:35465754 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of IGF1 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Igfbp5 |
insulin-like growth factor binding protein 5 |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of IGFBP5 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 9:74,452,371...74,464,953
Ensembl chr 9:74,448,382...74,465,156
|
|
G |
Il10ra |
interleukin 10 receptor subunit alpha |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of IL10RA mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 8:45,563,009...45,578,041
Ensembl chr 8:45,563,137...45,578,061
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
EXP |
Fluvastatin inhibits the reaction [bisphenol A results in increased expression of IL18 protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in increased expression of IL18 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in increased expression of IL18 protein]] |
CTD |
PMID:35465754 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression |
EXP |
fluvastatin results in decreased expression of IL1B mRNA |
CTD |
PMID:28951255 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2rg |
interleukin 2 receptor subunit gamma |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of IL2RG mRNA |
CTD |
PMID:16996129 |
|
NCBI chr X:66,395,330...66,399,026
Ensembl chr X:66,392,542...66,399,823
|
|
G |
Irf4 |
interferon regulatory factor 4 |
decreases expression |
ISO |
Fluvastatin results in decreased expression of IRF4 protein |
CTD |
PMID:33034787 |
|
NCBI chr17:33,721,800...33,742,570
Ensembl chr17:33,721,811...33,740,070
|
|
G |
Kat2b |
lysine acetyltransferase 2B |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of KAT2B mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 9:6,562,525...6,667,064
Ensembl chr 9:6,562,288...6,667,064
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions increases activity |
ISO |
[APOB gene SNP co-treated with APOE gene SNP co-treated with HMGCR gene SNP co-treated with LDLR gene SNP co-treated with PCSK9 gene SNP co-treated with ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to fluvastatin; fluvastatin promotes the reaction [Cholesterol, LDL binds to LDLR protein]; fluvastatin promotes the reaction [Indomethacin promotes the reaction [Cholesterol, LDL binds to LDLR protein]] fluvastatin results in increased activity of LDLR protein |
CTD |
PMID:8593127 PMID:10395027 PMID:19773416 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lhb |
luteinizing hormone subunit beta |
multiple interactions |
EXP |
Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of LHB protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of LHB protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of LHB protein]] |
CTD |
PMID:35465754 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Lipc |
lipase C, hepatic type |
multiple interactions |
ISO |
[ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to fluvastatin; [APOB gene SNP co-treated with APOE gene SNP co-treated with HMGCR gene SNP co-treated with LDLR gene SNP co-treated with PCSK9 gene SNP co-treated with ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to fluvastatin |
CTD |
PMID:19773416 |
|
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
|
|
G |
Lmna |
lamin A/C |
decreases farnesylation |
ISO |
fluvastatin results in decreased farnesylation of LMNA protein |
CTD |
PMID:16996129 |
|
NCBI chr 2:173,939,751...173,960,423
Ensembl chr 2:173,939,751...173,960,423
|
|
G |
Lpl |
lipoprotein lipase |
multiple interactions |
ISO |
[ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to fluvastatin; [APOB gene SNP co-treated with APOE gene SNP co-treated with HMGCR gene SNP co-treated with LDLR gene SNP co-treated with PCSK9 gene SNP co-treated with ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to fluvastatin |
CTD |
PMID:19773416 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Lzts1 |
leucine zipper tumor suppressor 1 |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of LZTS1 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr16:20,542,756...20,598,204
Ensembl chr16:20,542,809...20,598,203
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
decreases expression |
ISO |
fluvastatin results in decreased expression of MCL1 protein |
CTD |
PMID:16996129 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Med23 |
mediator complex subunit 23 |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of MED23 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 1:20,490,315...20,558,461
Ensembl chr 1:20,490,315...20,537,463
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
multiple interactions |
EXP |
Fluvastatin inhibits the reaction [bisphenol A results in increased expression of MKI67 protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in increased expression of MKI67 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in increased expression of MKI67 protein]] |
CTD |
PMID:35465754 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions decreases expression |
ISO |
Amitrole inhibits the reaction [fluvastatin results in decreased expression of MMP2 mRNA] |
CTD |
PMID:24964743 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases expression multiple interactions |
ISO |
fluvastatin results in decreased expression of MMP9 mRNA Amitrole inhibits the reaction [fluvastatin results in decreased expression of MMP9 mRNA] |
CTD |
PMID:24964743 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mphosph8 |
M-phase phosphoprotein 8 |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of MPHOSPH8 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr15:30,800,546...30,828,415
Ensembl chr15:30,686,613...30,828,810
|
|
G |
Mstn |
myostatin |
increases expression |
ISO |
Fluvastatin results in increased expression of MSTN protein |
CTD |
PMID:33034787 |
|
NCBI chr 9:48,452,533...48,458,933
Ensembl chr 9:48,452,533...48,458,933
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
EXP |
Fluvastatin inhibits the reaction [bisphenol A results in increased phosphorylation of MTOR protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in increased phosphorylation of MTOR protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in increased phosphorylation of MTOR protein]] |
CTD |
PMID:35465754 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Ndc80 |
NDC80 kinetochore complex component |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of NDC80 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 9:111,407,191...111,440,921
Ensembl chr 9:111,407,191...111,440,924
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of NFE2L2 protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of NFE2L2 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of NFE2L2 protein]] |
CTD |
PMID:35465754 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
EXP |
Fluvastatin inhibits the reaction [bisphenol A results in increased expression of NLRP3 protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in increased expression of NLRP3 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in increased expression of NLRP3 protein]] |
CTD |
PMID:35465754 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression multiple interactions |
ISO |
fluvastatin results in increased expression of NOS2 mRNA; fluvastatin results in increased expression of NOS2 protein [[fluvastatin results in increased expression of NOS2] which results in increased abundance of Nitric Oxide] which results in decreased expression of TFRC; [fluvastatin results in increased expression of NOS2] which results in increased abundance of Nitric Oxide; [N-(3-(aminomethyl)benzyl)acetamidine results in decreased activity of NOS2 protein] inhibits the reaction [fluvastatin results in increased abundance of Nitric Oxide]; Mevalonic Acid inhibits the reaction [fluvastatin results in increased expression of NOS2 protein] |
CTD |
PMID:24964743 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions |
EXP |
[fluvastatin co-treated with Valsartan] results in increased expression of NOS3 mRNA |
CTD |
PMID:28951255 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nphs1 |
NPHS1 adhesion molecule, nephrin |
increases expression multiple interactions |
ISO EXP |
fluvastatin increases expression of Nphs1 protein in kidney Fluvastatin inhibits the reaction [Puromycin Aminonucleoside results in decreased expression of NPHS1 mRNA] |
CTD RGD |
PMID:16452496 PMID:19188342 |
RGD:38596324 |
NCBI chr 1:85,720,812...85,749,079
Ensembl chr 1:85,720,812...85,749,078
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity multiple interactions |
ISO |
fluvastatin results in increased activity of NR1I2 protein [Fluvastatin co-treated with NR1I2 protein] results in increased expression of CYP3A4 mRNA; [Fluvastatin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA; [Fluvastatin co-treated with NR1I2 protein] results in increased expression of SGK2 mRNA |
CTD |
PMID:15802384 PMID:24204015 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
increases activity |
ISO EXP |
fluvastatin results in increased activity of NR1I3 protein |
CTD |
PMID:15802384 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Optn |
optineurin |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of OPTN mRNA |
CTD |
PMID:16996129 |
|
NCBI chr17:73,209,572...73,260,251
Ensembl chr17:73,209,575...73,260,251
|
|
G |
Pals1 |
protein associated with LIN7 1, MAGUK p55 family member |
multiple interactions |
ISO |
[Zoledronic Acid co-treated with Fluvastatin] results in increased expression of PALS1 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 6:97,548,133...97,654,163
Ensembl chr 6:97,548,630...97,653,305
|
|
G |
Pappa2 |
pappalysin 2 |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of PAPPA2 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr13:70,873,918...71,147,874
Ensembl chr13:70,876,794...71,147,779
|
|
G |
Pcsk9 |
proprotein convertase subtilisin/kexin type 9 |
multiple interactions |
ISO |
[APOB gene SNP co-treated with APOE gene SNP co-treated with HMGCR gene SNP co-treated with LDLR gene SNP co-treated with PCSK9 gene SNP co-treated with ABCA1 gene SNP co-treated with CETP gene SNP co-treated with LIPC gene SNP co-treated with LPL gene SNP] affects the susceptibility to fluvastatin |
CTD |
PMID:19773416 |
|
NCBI chr 5:121,211,278...121,233,688
Ensembl chr 5:121,211,278...121,233,688
|
|
G |
Pon1 |
paraoxonase 1 |
multiple interactions decreases activity |
EXP |
fluvastatin inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; fluvastatin inhibits the reaction [PON1 protein results in increased hydrolysis of phenylacetic acid] fluvastatin results in decreased activity of PON1 protein |
CTD |
PMID:14668577 |
|
NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
fluvastatin promotes the reaction [Bezafibrate results in increased activity of [PPARA protein binds to RXRA protein]] |
CTD |
PMID:11779144 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppp1r12a |
protein phosphatase 1, regulatory subunit 12A |
multiple interactions |
EXP |
fluvastatin inhibits the reaction [Puromycin Aminonucleoside results in increased expression of PPP1R12A protein modified form] |
CTD |
PMID:16452496 |
|
NCBI chr 7:43,482,808...43,593,689
Ensembl chr 7:43,482,803...43,593,425
|
|
G |
Ppp1r15a |
protein phosphatase 1, regulatory subunit 15A |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of PPP1R15A mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 1:96,000,053...96,003,128
Ensembl chr 1:96,000,058...96,003,171
|
|
G |
Prdx3 |
peroxiredoxin 3 |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of PRDX3 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 1:260,001,642...260,014,064
Ensembl chr 1:260,001,637...260,014,111
|
|
G |
Procr |
protein C receptor |
increases expression |
ISO |
fluvastatin results in increased expression of PROCR protein |
CTD |
PMID:16142594 |
|
NCBI chr 3:144,254,596...144,258,863
Ensembl chr 3:144,254,380...144,258,903
|
|
G |
Ptgis |
prostaglandin I2 synthase |
increases expression |
ISO |
Fluvastatin increases expression of PTGIS mRNA in umbilical vein endothelial cells |
RGD |
PMID:21213109 |
RGD:401901154 |
NCBI chr 3:155,928,564...155,964,228
Ensembl chr 3:155,916,412...155,965,451
|
|
G |
Rab27b |
RAB27B, member RAS oncogene family |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of RAB27B mRNA |
CTD |
PMID:16996129 |
|
NCBI chr18:63,597,554...63,794,124
Ensembl chr18:63,600,937...63,757,180
|
|
G |
Rab32 |
RAB32, member RAS oncogene family |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of RAB32 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 1:4,946,193...4,961,003
Ensembl chr 1:4,945,036...4,960,934
|
|
G |
Rab5b |
RAB5B, member RAS oncogene family |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of RAB5B mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 7:1,109,449...1,128,348
Ensembl chr 7:1,109,454...1,128,268
|
|
G |
Rabgap1l |
RAB GTPase activating protein 1-like |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of RABGAP1L mRNA |
CTD |
PMID:16996129 |
|
NCBI chr13:72,464,114...73,059,845
Ensembl chr13:72,468,110...73,059,984
|
|
G |
Rap1a |
RAP1A, member of RAS oncogene family |
decreases prenylation |
ISO |
fluvastatin results in decreased prenylation of RAP1A protein |
CTD |
PMID:16996129 |
|
NCBI chr 2:193,208,631...193,286,513
Ensembl chr 2:193,208,635...193,286,501
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases phosphorylation |
ISO |
fluvastatin results in decreased phosphorylation of RB1 protein |
CTD |
PMID:16996129 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rel |
REL proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Fluvastatin inhibits the reaction [Lipopolysaccharides promotes the reaction [[REL protein binds to RELA protein] which binds to F3 promoter]] |
CTD |
PMID:9081680 |
|
NCBI chr14:97,690,105...97,721,194
Ensembl chr14:97,695,161...97,720,892
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Fluvastatin inhibits the reaction [Lipopolysaccharides promotes the reaction [[REL protein binds to RELA protein] which binds to F3 promoter]] |
CTD |
PMID:9081680 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rgs11 |
regulator of G-protein signaling 11 |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of RGS11 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr10:15,222,804...15,231,062
Ensembl chr10:15,222,803...15,231,060
|
|
G |
Rhoa |
ras homolog family member A |
multiple interactions |
ISO EXP |
fluvastatin inhibits the reaction [Puromycin Aminonucleoside results in increased expression of RHOA protein] |
CTD |
PMID:16452496 |
|
NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Rhob |
ras homolog family member B |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of RHOB mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 6:31,363,752...31,365,926
Ensembl chr 6:31,363,548...31,366,108
|
|
G |
Rims2 |
regulating synaptic membrane exocytosis 2 |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of RIMS2 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 7:70,248,104...70,759,134
Ensembl chr 7:70,243,872...70,757,491
|
|
G |
Rin2 |
Ras and Rab interactor 2 |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of RIN2 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 3:133,086,858...133,303,604
Ensembl chr 3:133,086,749...133,303,604
|
|
G |
RT1-Ba |
RT1 class II, locus Ba |
affects expression |
ISO |
fluvastatin affects the expression of HLA-DQA1 mRNA |
CTD |
PMID:25811541 |
|
NCBI chr20:4,575,134...4,579,727
Ensembl chr20:4,575,134...4,579,744
|
|
G |
Rxra |
retinoid X receptor alpha |
multiple interactions |
ISO |
fluvastatin promotes the reaction [Bezafibrate results in increased activity of [PPARA protein binds to RXRA protein]] |
CTD |
PMID:11779144 |
|
NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712
|
|
G |
Sgk1 |
serum/glucocorticoid regulated kinase 1 |
affects expression |
EXP |
fluvastatin affects the expression of SGK1 mRNA; fluvastatin affects the expression of SGK1 protein |
CTD |
PMID:16696316 |
|
NCBI chr 1:22,980,257...23,098,122
Ensembl chr 1:22,980,261...23,098,283
|
|
G |
Sgk2 |
serum/glucocorticoid regulated kinase 2 |
multiple interactions |
ISO |
[fluvastatin co-treated with NR1I2 protein] results in increased expression of SGK2 mRNA |
CTD |
PMID:24204015 |
|
NCBI chr 3:151,644,102...151,669,480
Ensembl chr 3:151,644,102...151,669,480
|
|
G |
Slc15a1 |
solute carrier family 15 member 1 |
decreases activity |
ISO |
fluvastatin results in decreased activity of SLC15A1 protein |
CTD |
PMID:15846457 |
|
NCBI chr15:98,537,641...98,582,544
Ensembl chr15:98,537,641...98,582,545
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
affects import |
ISO |
SLCO1B3 protein affects the import of fluvastatin |
CTD |
PMID:16046661 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Slco2b1 |
solute carrier organic anion transporter family, member 2b1 |
affects import |
ISO |
SLCO2B1 protein affects the import of Fluvastatin |
CTD |
PMID:16046661 |
|
NCBI chr 1:153,959,288...154,007,294
Ensembl chr 1:153,959,293...154,007,353
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions increases expression |
ISO |
[fluvastatin co-treated with Doxorubicin] results in increased expression of SOD2 protein fluvastatin results in increased expression of SOD2 mRNA; fluvastatin results in increased expression of SOD2 protein [fluvastatin results in decreased expression of DDB2] which results in increased expression of SOD2 mRNA; Mevalonic Acid inhibits the reaction [fluvastatin results in increased expression of SOD2 protein] |
CTD |
PMID:19147586 PMID:24964743 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sos2 |
SOS Ras/Rho guanine nucleotide exchange factor 2 |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of SOS2 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 6:88,042,966...88,156,140
Ensembl chr 6:88,042,966...88,156,692
|
|
G |
Spin2a |
spindlin family member 2A |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of SPIN2A mRNA |
CTD |
PMID:16996129 |
|
NCBI chr X:17,511,018...17,513,001
Ensembl chr X:17,511,022...17,513,001
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
multiple interactions |
EXP |
fluvastatin inhibits the reaction [Puromycin Aminonucleoside results in increased expression of SPP1 mRNA] |
CTD |
PMID:16452496 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Tfpi |
tissue factor pathway inhibitor |
increases expression |
ISO |
fluvastatin results in increased expression of TFPI protein |
CTD |
PMID:16142594 |
|
NCBI chr 3:69,533,156...69,582,547
Ensembl chr 3:69,533,156...69,576,880
|
|
G |
Tfrc |
transferrin receptor |
multiple interactions decreases expression |
ISO |
[[fluvastatin results in increased expression of NOS2] which results in increased abundance of Nitric Oxide] which results in decreased expression of TFRC; [fluvastatin results in decreased expression of TFRC protein] which results in decreased uptake of Iron; Amitrole inhibits the reaction [fluvastatin results in decreased expression of TFRC protein]; Mevalonic Acid inhibits the reaction [fluvastatin results in decreased expression of TFRC mRNA]; Mevalonic Acid inhibits the reaction [fluvastatin results in decreased expression of TFRC protein]; N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [fluvastatin results in decreased expression of TFRC protein] fluvastatin results in decreased expression of TFRC mRNA; fluvastatin results in decreased expression of TFRC protein |
CTD |
PMID:24964743 |
|
NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
affects expression multiple interactions |
EXP |
fluvastatin affects the expression of TGFB1 protein Fluvastatin inhibits the reaction [bisphenol A results in increased expression of TGFB1 protein]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in increased expression of TGFB1 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in increased expression of TGFB1 protein]] |
CTD |
PMID:16696316 PMID:35465754 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnfrsf10b |
TNF receptor superfamily member 10b |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of TNFRSF10A mRNA |
CTD |
PMID:16996129 |
|
NCBI chr15:44,840,386...44,868,318
Ensembl chr15:44,840,386...44,867,467
|
|
G |
Tp53inp1 |
tumor protein p53 inducible nuclear protein 1 |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of TP53INP1 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 5:24,253,986...24,272,250
Ensembl chr 5:24,260,568...24,267,968
|
|
G |
Vim |
vimentin |
multiple interactions |
EXP |
fluvastatin inhibits the reaction [Puromycin Aminonucleoside results in increased expression of VIM mRNA] |
CTD |
PMID:16452496 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Wnt11 |
Wnt family member 11 |
multiple interactions |
ISO |
[zoledronic acid co-treated with fluvastatin] results in increased expression of WNT11 mRNA |
CTD |
PMID:16996129 |
|
NCBI chr 1:153,134,503...153,154,294
Ensembl chr 1:153,138,197...153,154,294
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
increases expression decreases expression multiple interactions |
ISO |
Lovastatin results in increased expression of ABCA1 mRNA lovastatin decreases expression of ABCA1 mRNA in HepG2 cells [Dietary Fats co-treated with Lovastatin] affects the expression of ABCA1 mRNA Lovastatin results in decreased expression of ABCA1 mRNA |
CTD RGD |
PMID:19260826 PMID:29852127 PMID:27765770 |
RGD:18936994 |
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions decreases activity |
ISO |
Lovastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Lovastatin results in decreased activity of ABCB11 protein |
CTD |
PMID:23956101 PMID:24014644 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions decreases activity increases transport |
ISO |
Lovastatin analog inhibits the reaction [ABCB1 protein results in increased transport of calcein AM] Lovastatin analog results in decreased activity of ABCB1 protein ABCB1 protein results in increased transport of Lovastatin; ABCB1 protein results in increased transport of Lovastatin analog |
CTD |
PMID:15616150 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
decreases activity multiple interactions |
ISO |
Lovastatin results in decreased activity of ABCC1 protein [Lovastatin results in decreased activity of ABCC1 protein] which results in increased susceptibility to Antimony Sodium Gluconate; Doxorubicin inhibits the reaction [Lovastatin results in increased expression of ABCC1 mRNA] |
CTD |
PMID:18056276 PMID:22712078 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions increases expression decreases activity |
ISO EXP |
ABCC2 protein binds to and results in increased uptake of Lovastatin analog; Lovastatin analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein]; Lovastatin analog inhibits the reaction [ABCC2 protein results in increased transport of calcein AM] Lovastatin results in increased expression of ABCC2 mRNA Lovastatin analog results in decreased activity of ABCC2 protein ABCC2 protein binds to and results in increased uptake of Lovastatin analog; Lovastatin analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein]; Lovastatin analog inhibits the reaction [ABCC2 protein results in increased transport of calcein AM]; Lovastatin promotes the reaction [Cisplatin results in decreased expression of ABCC2 mRNA] |
CTD |
PMID:15616150 PMID:23562342 PMID:26739623 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
affects expression multiple interactions |
ISO |
Lovastatin affects the expression of ABCG5 mRNA [Dietary Fats co-treated with Lovastatin] affects the expression of ABCG5 mRNA |
CTD |
PMID:27208389 PMID:29852127 |
|
NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
affects expression |
ISO |
Lovastatin affects the expression of ABCG8 mRNA |
CTD |
PMID:27208389 |
|
NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of ACACA mRNA |
CTD |
PMID:29852127 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of ACOX1 mRNA |
CTD |
PMID:29852127 |
|
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Acss2 |
acyl-CoA synthetase short-chain family member 2 |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of ACSS2 mRNA |
CTD |
PMID:29852127 |
|
NCBI chr 3:144,003,808...144,047,452
Ensembl chr 3:144,004,336...144,059,675
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions decreases expression |
ISO |
Lovastatin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] Lovastatin results in decreased expression of ACTA2 protein |
CTD |
PMID:22129737 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Actb |
actin, beta |
decreases expression increases expression |
ISO |
Lovastatin results in decreased expression of ACTB mRNA Lovastatin results in increased expression of ACTB mRNA |
CTD |
PMID:20493250 |
|
NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877
|
|
G |
Actr3 |
actin related protein 3 |
increases expression |
ISO |
Lovastatin results in increased expression of ACTR3 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr13:36,800,739...36,843,837
Ensembl chr13:36,800,093...36,844,124
|
|
G |
Adam10 |
ADAM metallopeptidase domain 10 |
increases expression multiple interactions |
EXP ISO |
Lovastatin results in increased expression of ADAM10 protein [Lovastatin co-treated with APP protein] results in increased expression of ADAM10 protein |
CTD |
PMID:29341888 |
|
NCBI chr 8:71,346,008...71,477,889
Ensembl chr 8:71,345,837...71,477,889
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
affects expression multiple interactions |
ISO |
Lovastatin affects the expression of ADIPOQ mRNA [Dietary Fats co-treated with Lovastatin] affects the expression of ADIPOQ mRNA |
CTD |
PMID:27208389 PMID:29852127 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Ahcy |
adenosylhomocysteinase |
decreases expression |
ISO |
Lovastatin results in decreased expression of AHCY mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 3:143,569,134...143,584,359
Ensembl chr 3:143,569,094...143,584,393
|
|
G |
Akap7 |
A-kinase anchoring protein 7 |
decreases response to substance |
ISO |
AKAP7 SNP results in decreased susceptibility to Lovastatin |
CTD |
PMID:21483694 |
|
NCBI chr 1:20,087,190...20,217,799
Ensembl chr 1:20,087,373...20,217,797
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases phosphorylation |
ISO EXP |
Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein] Lovastatin inhibits the reaction [Cholesterol, Dietary results in decreased expression of AKT1 protein] Lovastatin results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:16425225 PMID:17472962 PMID:19760159 PMID:20578043 PMID:35734936 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alox15 |
arachidonate 15-lipoxygenase |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased activity of ALOX15 protein] |
CTD |
PMID:35734936 |
|
NCBI chr10:55,060,169...55,068,885
Ensembl chr10:55,060,412...55,068,874
|
|
G |
Ank2 |
ankyrin 2 |
decreases response to substance |
ISO |
ANK2 SNP results in decreased susceptibility to Lovastatin |
CTD |
PMID:21483694 |
|
NCBI chr 2:215,378,028...215,954,015
Ensembl chr 2:215,379,680...215,862,923
|
|
G |
Anxa4 |
annexin A4 |
decreases expression |
ISO |
Lovastatin results in decreased expression of ANXA4 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 4:119,184,378...119,241,183
Ensembl chr 4:119,184,374...119,241,161
|
|
G |
Anxa5 |
annexin A5 |
decreases expression |
ISO |
Lovastatin results in decreased expression of ANXA5 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 2:119,314,007...119,344,703
Ensembl chr 2:119,314,007...119,353,369
|
|
G |
Apoa1 |
apolipoprotein A1 |
multiple interactions |
ISO |
[Lovastatin co-treated with Niacin] results in increased expression of APOA1 protein; [Niacin co-treated with Lovastatin] results in increased expression of APOA1 protein |
CTD |
PMID:12633795 PMID:17319473 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apob |
apolipoprotein B |
multiple interactions decreases secretion |
ISO |
[Niacin co-treated with Lovastatin] results in decreased expression of APOB protein Lovastatin results in decreased secretion of APOB protein |
CTD |
PMID:11728391 PMID:12633795 |
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Apoe |
apolipoprotein E |
affects expression multiple interactions |
ISO |
Lovastatin affects the expression of APOE mRNA [Dietary Fats co-treated with Lovastatin] affects the expression of APOE mRNA |
CTD |
PMID:27208389 PMID:29852127 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions increases cleavage increases secretion |
EXP ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lovastatin results in increased secretion of APP protein modified form]; TAPI-2 inhibits the reaction [Lovastatin results in increased secretion of APP protein modified form]; U 0126 inhibits the reaction [Lovastatin results in increased secretion of APP protein] [APP protein co-treated with Lovastatin] results in increased secretion of APP protein; [Lovastatin co-treated with APP protein] results in decreased expression of BACE1 protein; [Lovastatin co-treated with APP protein] results in increased expression of ADAM10 protein; [Lovastatin co-treated with APP protein] results in increased expression of BACE2 protein; [Lovastatin co-treated with APP protein] results in increased expression of CHRNA7 protein; [Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK1 protein; [Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK3 protein; Lovastatin affects the reaction [[MAPK1 protein co-treated with APP protein] affects the expression of APP protein]; Lovastatin affects the reaction [[MAPK1 protein co-treated with APP protein] affects the expression of CHRNA7 protein]; Lovastatin affects the reaction [[MAPK3 protein co-treated with APP protein] affects the expression of APP protein]; Lovastatin affects the reaction [[MAPK3 protein co-treated with APP protein] affects the expression of CHRNA7 protein]; U 0126 inhibits the reaction [[APP protein co-treated with Lovastatin] results in increased secretion of APP protein]; U 0126 inhibits the reaction [[Lovastatin co-treated with APP protein] results in increased expression of CHRNA7 protein]; U 0126 inhibits the reaction [[Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [[Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK3 protein] Lovastatin results in increased cleavage of APP protein Lovastatin results in increased secretion of APP protein; Lovastatin results in increased secretion of APP protein modified form |
CTD |
PMID:19741129 PMID:29341888 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Arhgdia |
Rho GDP dissociation inhibitor alpha |
increases expression |
ISO |
Lovastatin results in increased expression of ARHGDIA mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:105,854,526...105,858,020
Ensembl chr10:105,854,533...105,858,023
|
|
G |
Asic3 |
acid sensing ion channel subunit 3 |
increases expression |
ISO |
Lovastatin results in increased expression of ASIC3 mRNA |
CTD |
PMID:38432573 |
|
NCBI chr 4:10,760,509...10,764,987
Ensembl chr 4:10,760,597...10,764,643
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [Cisplatin results in increased expression of ATM protein modified form] |
CTD |
PMID:26739623 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Atr |
ATR serine/threonine kinase |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [Cisplatin results in increased expression of ATR protein modified form] |
CTD |
PMID:26739623 |
|
NCBI chr 8:96,426,704...96,524,152
Ensembl chr 8:96,426,724...96,524,136
|
|
G |
Bace1 |
beta-secretase 1 |
decreases expression multiple interactions |
EXP ISO |
Lovastatin results in decreased expression of BACE1 protein [Lovastatin co-treated with APP protein] results in decreased expression of BACE1 protein |
CTD |
PMID:29341888 |
|
NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876
|
|
G |
Bace2 |
beta-secretase 2 |
multiple interactions increases expression |
ISO EXP |
[Lovastatin co-treated with APP protein] results in increased expression of BACE2 protein Lovastatin results in increased expression of BACE2 protein |
CTD |
PMID:29341888 |
|
NCBI chr11:36,707,447...36,789,550
Ensembl chr11:36,707,458...36,789,546
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions affects localization |
ISO EXP |
Lovastatin results in increased expression of BAX protein Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of BAX protein]; Lovastatin promotes the reaction [Cisplatin results in increased expression of BAX mRNA] Lovastatin affects the localization of BAX protein |
CTD |
PMID:10473109 PMID:15180944 PMID:26739623 PMID:35734936 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcar1 |
BCAR1 scaffold protein, Cas family member |
increases cleavage multiple interactions |
EXP |
Lovastatin results in increased cleavage of BCAR1 protein Mevalonic Acid inhibits the reaction [Lovastatin results in increased cleavage of BCAR1 protein] |
CTD |
PMID:16367743 |
|
NCBI chr19:39,679,215...39,713,907
Ensembl chr19:39,679,204...39,713,907
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO EXP |
Lovastatin results in decreased expression of BCL2 protein Lovastatin inhibits the reaction [Cholesterol, Dietary results in decreased expression of BCL2 protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in decreased expression of BCL2 protein] |
CTD |
PMID:10473109 PMID:11178870 PMID:12094262 PMID:35734936 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression multiple interactions |
EXP |
Lovastatin results in decreased expression of BCL2L1 protein Mevalonic Acid inhibits the reaction [Lovastatin results in decreased expression of BCL2L1 protein] |
CTD |
PMID:11178870 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
multiple interactions increases expression |
ISO EXP |
pyrazolanthrone inhibits the reaction [Lovastatin results in increased expression of BCL2L11 protein] Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of BCL2L11 protein] |
CTD |
PMID:18766339 PMID:35734936 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased expression of BDNF protein] |
CTD |
PMID:24718106 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions decreases expression |
ISO |
farnesyl pyrophosphate inhibits the reaction [Lovastatin results in decreased expression of BIRC5 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in decreased expression of BIRC5 protein] |
CTD |
PMID:17472962 PMID:18815881 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Brca2 |
BRCA2, DNA repair associated |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of BRCA2 mRNA] |
CTD |
PMID:22712078 |
|
NCBI chr12:59,492...103,789
Ensembl chr12:59,819...100,567
|
|
G |
C1qbp |
complement C1q binding protein |
increases expression |
ISO |
Lovastatin results in increased expression of C1QBP mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:55,699,954...55,704,605
Ensembl chr10:55,699,954...55,704,649
|
|
G |
Calr |
calreticulin |
increases expression |
ISO |
Lovastatin results in increased expression of CALR mRNA |
CTD |
PMID:20493250 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Camk2b |
calcium/calmodulin-dependent protein kinase II beta |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of CAMK2B protein] |
CTD |
PMID:24718106 |
|
NCBI chr14:80,845,206...80,934,172
Ensembl chr14:80,845,238...80,933,994
|
|
G |
Casp2 |
caspase 2 |
increases activity multiple interactions |
ISO |
Lovastatin results in increased activity of CASP2 protein Lovastatin promotes the reaction [RHOB protein binds to CASP2 protein] |
CTD |
PMID:12933658 PMID:16234849 |
|
NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage increases activity decreases expression |
ISO EXP |
farnesyl pyrophosphate inhibits the reaction [Lovastatin results in increased activity of and results in increased cleavage of CASP3 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased activity of and results in increased cleavage of CASP3 protein] Lovastatin analog results in increased cleavage of CASP3 protein Lovastatin results in increased activity of CASP3 protein Lovastatin results in decreased expression of CASP3 mRNA Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of CASP3 protein]; Lovastatin results in increased activity of and results in increased cleavage of CASP3 protein; Mevalonic Acid inhibits the reaction [Lovastatin results in increased activity of and results in increased cleavage of CASP3 protein] |
CTD |
PMID:11720884 PMID:12933658 PMID:15180944 PMID:16367743 PMID:18034278 PMID:18766339 PMID:20493250 PMID:26863638 PMID:35734936 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp6 |
caspase 6 |
increases activity |
ISO |
Lovastatin results in increased activity of CASP6 protein |
CTD |
PMID:11720884 |
|
NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502
|
|
G |
Casp8 |
caspase 8 |
increases activity |
ISO |
Lovastatin results in increased activity of CASP8 protein |
CTD |
PMID:15180944 PMID:15705602 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases activity multiple interactions |
ISO EXP |
Lovastatin results in increased activity of CASP9 protein Lovastatin inhibits the reaction [Cholesterol, Dietary results in decreased expression of CASP9 protein] |
CTD |
PMID:12933658 PMID:15180944 PMID:15705602 PMID:35734936 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [Cholesterol, Dietary results in decreased activity of CAT protein] |
CTD |
PMID:35734936 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of CCN2 mRNA]; Lovastatin inhibits the reaction [Epirubicin results in increased expression of CCN2 mRNA] |
CTD |
PMID:22712078 PMID:28710503 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression increases expression |
ISO EXP |
Lovastatin results in decreased expression of CCND1 protein Lovastatin results in increased expression of CCND1 mRNA; Lovastatin results in increased expression of CCND1 protein |
CTD |
PMID:18034278 PMID:20578043 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd3 |
cyclin D3 |
decreases expression |
ISO |
Lovastatin results in decreased expression of CCND3 protein |
CTD |
PMID:10502407 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Cct5 |
chaperonin containing TCP1 subunit 5 |
increases expression |
ISO |
Lovastatin results in increased expression of CCT5 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 2:82,591,750...82,602,903
Ensembl chr 2:82,590,630...82,602,930
|
|
G |
Cct6a |
chaperonin containing TCP1 subunit 6A |
increases expression |
ISO |
Lovastatin results in increased expression of CCT6A mRNA |
CTD |
PMID:20493250 |
|
NCBI chr12:26,872,736...26,883,125
Ensembl chr12:26,872,574...26,883,337
|
|
G |
Cct8 |
chaperonin containing TCP1 subunit 8 |
decreases expression |
ISO |
Lovastatin results in decreased expression of CCT8 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr11:26,710,370...26,722,079
Ensembl chr11:26,710,370...26,722,079
|
|
G |
Cd40 |
CD40 molecule |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA] |
CTD |
PMID:17507688 |
|
NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
|
|
G |
Cd44 |
CD44 molecule |
decreases expression |
ISO |
Lovastatin results in decreased expression of CD44 mRNA; Lovastatin results in decreased expression of CD44 protein |
CTD |
PMID:21199873 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cdc42 |
cell division cycle 42 |
increases expression decreases expression |
ISO |
Lovastatin results in increased expression of CDC42 protein Lovastatin results in decreased expression of CDC42 mRNA |
CTD |
PMID:18766339 PMID:20493250 |
|
NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases activity |
ISO |
Lovastatin results in decreased activity of CDK2 protein |
CTD |
PMID:10502407 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases expression |
EXP |
Lovastatin results in decreased expression of CDK4 mRNA; Lovastatin results in decreased expression of CDK4 protein |
CTD |
PMID:20578043 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdk5 |
cyclin-dependent kinase 5 |
decreases cleavage |
EXP |
Lovastatin results in decreased cleavage of CDK5 protein |
CTD |
PMID:19741129 |
|
NCBI chr 4:10,754,682...10,760,110
Ensembl chr 4:10,754,687...10,760,112
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression multiple interactions |
ISO |
Lovastatin results in increased expression of CDKN1A protein Lovastatin inhibits the reaction [Doxorubicin results in increased expression of CDKN1A mRNA] |
CTD |
PMID:18034278 PMID:22712078 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression |
EXP ISO |
Lovastatin results in increased expression of CDKN1B mRNA; Lovastatin results in increased expression of CDKN1B protein |
CTD |
PMID:9848777 PMID:10502407 PMID:15118409 PMID:18034278 PMID:20578043 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn3 |
cyclin-dependent kinase inhibitor 3 |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [Cisplatin results in increased expression of CDKN3 protein modified form] |
CTD |
PMID:26739623 |
|
NCBI chr15:20,022,522...20,033,948
Ensembl chr15:20,022,664...20,033,945
|
|
G |
Cenpf |
centromere protein F |
increases expression multiple interactions |
ISO |
Lovastatin results in increased expression of CENPF protein Lovastatin promotes the reaction [Paclitaxel results in increased expression of CENPF protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in increased expression of CENPF protein] |
CTD |
PMID:12467231 |
|
NCBI chr13:101,184,127...101,229,714
Ensembl chr13:101,184,127...101,229,669
|
|
G |
Cfl1 |
cofilin 1 |
decreases phosphorylation |
EXP |
Lovastatin results in decreased phosphorylation of CFL1 protein |
CTD |
PMID:20578043 |
|
NCBI chr 1:202,796,012...202,801,337
Ensembl chr 1:202,786,627...202,817,587
|
|
G |
Chek1 |
checkpoint kinase 1 |
multiple interactions |
ISO EXP |
Lovastatin inhibits the reaction [Cisplatin results in increased phosphorylation of CHEK1 protein]; Lovastatin inhibits the reaction [Doxorubicin results in increased phosphorylation of CHEK1 protein] Lovastatin inhibits the reaction [Cisplatin results in increased expression of CHEK1 protein modified form] |
CTD |
PMID:17088865 PMID:21356574 PMID:26739623 |
|
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Chek2 |
checkpoint kinase 2 |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [Cisplatin results in increased expression of CHEK2 protein modified form] |
CTD |
PMID:26739623 |
|
NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286
|
|
G |
Chrna7 |
cholinergic receptor nicotinic alpha 7 subunit |
multiple interactions increases expression |
ISO EXP |
[Lovastatin co-treated with APP protein] results in increased expression of CHRNA7 protein; Lovastatin affects the reaction [[MAPK1 protein co-treated with APP protein] affects the expression of CHRNA7 protein]; Lovastatin affects the reaction [[MAPK3 protein co-treated with APP protein] affects the expression of CHRNA7 protein]; U 0126 inhibits the reaction [[Lovastatin co-treated with APP protein] results in increased expression of CHRNA7 protein] Lovastatin results in increased expression of CHRNA7 mRNA; Lovastatin results in increased expression of CHRNA7 protein U 0126 inhibits the reaction [Lovastatin results in increased expression of CHRNA7 protein] |
CTD |
PMID:29341888 |
|
NCBI chr 1:116,711,559...116,837,269
Ensembl chr 1:116,714,711...116,837,240
|
|
G |
Clic1 |
chloride intracellular channel 1 |
decreases expression |
ISO |
Lovastatin results in decreased expression of CLIC1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr20:3,764,867...3,773,711
Ensembl chr20:3,761,461...3,773,712
|
|
G |
Cox5a |
cytochrome c oxidase subunit 5A |
increases expression |
ISO |
Lovastatin results in increased expression of COX5A mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 8:57,922,374...57,933,781
Ensembl chr 8:57,922,290...57,933,781
|
|
G |
Cp |
ceruloplasmin |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of CP protein] |
CTD |
PMID:35734936 |
|
NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased phosphorylation of CREB1 protein] |
CTD |
PMID:24718106 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crk |
CRK proto-oncogene, adaptor protein |
increases expression |
ISO |
Lovastatin results in increased expression of CRK mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:60,530,469...60,556,703
Ensembl chr10:60,530,464...60,553,406
|
|
G |
Crp |
C-reactive protein |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of CRP protein] |
CTD |
PMID:35734936 |
|
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Ctnnb1 |
catenin beta 1 |
decreases degradation increases expression multiple interactions |
EXP ISO |
Lovastatin results in decreased degradation of CTNNB1 protein Lovastatin results in increased expression of CTNNB1 mRNA Lovastatin affects the localization of and results in increased expression of CTNNB1 protein |
CTD |
PMID:17234346 PMID:19741129 PMID:24742230 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of CYP1A1 mRNA]; Lovastatin results in increased expression of and results in increased activity of CYP1A1 protein Lovastatin results in increased expression of CYP1A1 mRNA |
CTD |
PMID:1311272 PMID:22712078 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
Lovastatin results in decreased activity of CYP1B1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
decreases activity |
ISO |
Lovastatin results in decreased activity of CYP2C8 protein |
CTD |
PMID:15601807 |
|
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions increases expression |
ISO |
[Lovastatin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA Lovastatin results in increased expression of CYP3A4 mRNA |
CTD |
PMID:12505310 PMID:17041008 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Dctn2 |
dynactin subunit 2 |
decreases expression |
ISO |
Lovastatin results in decreased expression of DCTN2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 7:63,092,061...63,107,560
Ensembl chr 7:63,092,057...63,108,543
|
|
G |
Ddt |
D-dopachrome tautomerase |
decreases expression |
ISO |
Lovastatin results in decreased expression of DDT mRNA |
CTD |
PMID:20493250 |
|
NCBI chr20:12,884,216...12,886,687
Ensembl chr20:12,884,243...12,888,482
|
|
G |
Dlg3 |
discs large MAGUK scaffold protein 3 |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of DLG3 protein] |
CTD |
PMID:24718106 |
|
NCBI chr X:65,859,653...65,911,887
Ensembl chr X:65,860,172...65,910,322
|
|
G |
Dlst |
dihydrolipoamide S-succinyltransferase |
decreases expression |
ISO |
Lovastatin results in decreased expression of DLST mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 6:104,758,511...104,783,296
Ensembl chr 6:104,758,631...104,783,296
|
|
G |
Dock7 |
dedicator of cytokinesis 7 |
increases expression |
ISO |
Lovastatin results in increased expression of DOCK7 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 5:113,599,371...113,782,871
Ensembl chr 5:113,600,198...113,782,813
|
|
G |
Dpysl2 |
dihydropyrimidinase-like 2 |
increases expression |
ISO |
Lovastatin results in increased expression of DPYSL2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr15:41,005,551...41,111,724
Ensembl chr15:41,005,551...41,111,829
|
|
G |
Dstn |
destrin, actin depolymerizing factor |
decreases expression |
ISO |
Lovastatin results in decreased expression of DSTN mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 3:131,284,647...131,311,361
Ensembl chr 3:131,284,648...131,311,379
|
|
G |
Eaf2 |
ELL associated factor 2 |
decreases response to substance |
ISO |
EAF2 SNP results in decreased susceptibility to Lovastatin |
CTD |
PMID:21483694 |
|
NCBI chr11:63,960,200...64,004,610
Ensembl chr11:63,960,200...64,004,610
|
|
G |
Eef2 |
eukaryotic translation elongation factor 2 |
decreases expression |
ISO |
Lovastatin results in decreased expression of EEF2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 7:8,533,248...8,538,518
Ensembl chr 7:8,533,116...8,559,183
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [EGF protein promotes the reaction [EGFR protein results in increased phosphorylation of EGFR protein]]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of RAF1 protein] |
CTD |
PMID:12942316 PMID:19760159 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [EGF protein promotes the reaction [EGFR protein results in increased phosphorylation of EGFR protein]]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] |
CTD |
PMID:12942316 PMID:19760159 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Eif3i |
eukaryotic translation initiation factor 3, subunit I |
decreases expression |
ISO |
Lovastatin results in decreased expression of EIF3I mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 5:141,935,135...141,942,589
Ensembl chr 5:141,935,044...141,942,676
|
|
G |
Ercc1 |
ERCC excision repair 1, endonuclease non-catalytic subunit |
increases expression multiple interactions |
EXP |
Lovastatin results in increased expression of ERCC1 mRNA Lovastatin promotes the reaction [Cisplatin results in increased expression of ERCC1 mRNA] |
CTD |
PMID:26739623 |
|
NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963
|
|
G |
Ercc5 |
ERCC excision repair 5, endonuclease |
multiple interactions increases expression |
EXP |
Lovastatin promotes the reaction [Cisplatin results in increased expression of ERCC5 mRNA] Lovastatin results in increased expression of ERCC5 mRNA |
CTD |
PMID:26739623 |
|
NCBI chr 9:46,309,477...46,354,478
Ensembl chr 9:46,309,389...46,354,472
|
|
G |
Ercc6 |
ERCC excision repair 6, chromatin remodeling factor |
increases expression |
EXP |
Lovastatin results in increased expression of ERCC6 mRNA |
CTD |
PMID:26739623 |
|
NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587
|
|
G |
Erp29 |
endoplasmic reticulum protein 29 |
decreases expression |
ISO |
Lovastatin results in decreased expression of ERP29 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr12:35,089,698...35,095,952
Ensembl chr12:35,089,707...35,096,376
|
|
G |
Fads2 |
fatty acid desaturase 2 |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of FADS2 mRNA |
CTD |
PMID:29852127 |
|
NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
ISO EXP |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of FAS mRNA] Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of FAS protein] |
CTD |
PMID:17088865 PMID:35734936 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of FASLG mRNA] |
CTD |
PMID:17088865 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fasn |
fatty acid synthase |
increases expression |
ISO |
Lovastatin results in increased expression of FASN mRNA |
CTD |
PMID:11728391 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fbxo32 |
F-box protein 32 |
multiple interactions increases expression |
ISO |
geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of FBXO32 mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of FBXO32 protein]; Lovastatin promotes the reaction [Fenofibrate results in increased expression of FBXO32 protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in increased expression of FBXO32 mRNA]; Mevalonic Acid inhibits the reaction [Lovastatin results in increased expression of FBXO32 protein] Lovastatin results in increased expression of FBXO32 mRNA; Lovastatin results in increased expression of FBXO32 protein |
CTD |
PMID:19406843 PMID:33408297 |
|
NCBI chr 7:89,731,428...89,764,997
Ensembl chr 7:89,730,232...89,765,436
|
|
G |
Fdft1 |
farnesyl diphosphate farnesyl transferase 1 |
increases activity |
ISO |
Lovastatin results in increased activity of FDFT1 protein |
CTD |
PMID:8517861 |
|
NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287
|
|
G |
Fdps |
farnesyl diphosphate synthase |
multiple interactions |
ISO EXP |
[Dietary Fats co-treated with Lovastatin] affects the expression of FDPS mRNA [Cholestyramine Resin co-treated with Lovastatin] results in increased expression of FDPS mRNA; Mevalonic Acid inhibits the reaction [[Cholestyramine Resin co-treated with Lovastatin] results in increased expression of FDPS mRNA] |
CTD |
PMID:3670308 PMID:29852127 |
|
NCBI chr 2:174,497,402...174,507,031
Ensembl chr 2:174,486,665...174,507,776
|
|
G |
Flot1 |
flotillin 1 |
decreases expression |
ISO |
Lovastatin results in decreased expression of FLOT1 protein |
CTD |
PMID:12628479 |
|
NCBI chr20:2,917,864...2,927,993
Ensembl chr20:2,917,137...2,927,978
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
affects expression multiple interactions decreases expression |
EXP ISO |
Lovastatin affects the expression of FOS protein Lovastatin inhibits the reaction [Doxorubicin results in increased expression of FOS mRNA] Lovastatin results in decreased expression of FOS |
CTD |
PMID:10412747 PMID:12392621 PMID:22712078 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosb |
FosB proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [benserazide, levodopa drug combination results in increased expression of FOSB protein] |
CTD |
PMID:18434508 |
|
NCBI chr 1:78,954,312...78,961,492
Ensembl chr 1:78,954,115...78,961,465
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions decreases phosphorylation |
ISO |
Lovastatin promotes the reaction [Fenofibrate results in increased expression of FOXO1 protein] Lovastatin results in decreased phosphorylation of FOXO1 protein |
CTD |
PMID:33034787 PMID:33408297 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Fscn1 |
fascin actin-bundling protein 1 |
decreases expression |
ISO |
Lovastatin results in decreased expression of FSCN1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr12:11,597,042...11,610,183
Ensembl chr12:11,597,048...11,610,211
|
|
G |
G3bp1 |
G3BP stress granule assembly factor 1 |
increases expression |
ISO |
Lovastatin results in increased expression of G3BP1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:39,586,864...39,620,268
Ensembl chr10:39,586,864...39,620,268
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of G6PD mRNA |
CTD |
PMID:29852127 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gale |
UDP-galactose-4-epimerase |
decreases expression |
ISO |
Lovastatin results in decreased expression of GALE mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 5:148,193,886...148,198,392
Ensembl chr 5:148,194,791...148,198,388
|
|
G |
Gap43 |
growth associated protein 43 |
increases expression |
ISO |
Lovastatin results in increased expression of GAP43 protein |
CTD |
PMID:20694854 |
|
NCBI chr11:58,376,371...58,470,047
Ensembl chr11:58,376,371...58,470,045
|
|
G |
Gdi2 |
GDP dissociation inhibitor 2 |
increases expression |
ISO |
Lovastatin results in increased expression of GDI2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr17:66,649,616...66,676,299
Ensembl chr17:66,649,619...66,676,366
|
|
G |
Gk |
glycerol kinase |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of GK mRNA |
CTD |
PMID:29852127 |
|
NCBI chr X:50,162,089...50,238,707
Ensembl chr X:50,163,123...50,238,631
|
|
G |
Gmps |
guanine monophosphate synthase |
increases expression |
ISO |
Lovastatin results in increased expression of GMPS mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 2:148,441,369...148,491,908
Ensembl chr 2:148,435,643...148,485,875
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of GPT protein; Lovastatin inhibits the reaction [Dietary Fats results in increased expression of GPT protein] |
CTD |
PMID:29852127 PMID:30853469 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of GPX1 mRNA] |
CTD |
PMID:28710503 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of GRIN2B protein] |
CTD |
PMID:24718106 |
|
NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
decreases phosphorylation increases phosphorylation |
ISO EXP |
Lovastatin results in decreased phosphorylation of GSK3B protein Lovastatin results in increased phosphorylation of GSK3B protein |
CTD |
PMID:17234346 PMID:19741129 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions |
ISO EXP |
Lovastatin inhibits the reaction [Cisplatin results in increased phosphorylation of H2AX protein] Lovastatin inhibits the reaction [Cisplatin results in increased expression of H2AX protein modified form] Lovastatin inhibits the reaction [Cisplatin results in increased expression of H2AX protein modified form]; Lovastatin inhibits the reaction [Doxorubicin results in increased expression of H2AX protein modified form]; Lovastatin inhibits the reaction [Doxorubicin results in increased phosphorylation of H2AX protein] |
CTD |
PMID:21356574 PMID:22712078 PMID:26739623 PMID:28710503 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Has1 |
hyaluronan synthase 1 |
increases expression |
ISO |
Lovastatin results in increased expression of HAS1 mRNA; Lovastatin results in increased expression of HAS1 protein |
CTD |
PMID:38432573 |
|
NCBI chr 1:58,693,411...58,705,653
Ensembl chr 1:58,693,411...58,705,397
|
|
G |
Has2 |
hyaluronan synthase 2 |
increases expression |
ISO |
Lovastatin results in increased expression of HAS2 mRNA |
CTD |
PMID:38432573 |
|
NCBI chr 7:88,113,326...88,139,337
Ensembl chr 7:88,113,326...88,128,933
|
|
G |
Hdac1 |
histone deacetylase 1 |
increases expression |
ISO |
Lovastatin results in increased expression of HDAC1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 5:141,853,992...141,881,057
Ensembl chr 5:141,853,989...141,881,111
|
|
G |
Hint1 |
histidine triad nucleotide binding protein 1 |
increases expression |
ISO |
Lovastatin results in increased expression of HINT1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:38,989,516...38,993,259
Ensembl chr 4:92,100,973...92,101,568
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions affects expression decreases activity increases expression |
ISO |
[Lovastatin results in decreased activity of HMGCR protein] which results in decreased abundance of farnesyl pyrophosphate; [Lovastatin results in decreased activity of HMGCR protein] which results in decreased abundance of geranylgeranyl pyrophosphate; Lovastatin inhibits the reaction [HMGCR protein results in increased abundance of geranyl diphosphate] [Dietary Fats co-treated with Lovastatin] affects the expression of HMGCR mRNA Lovastatin affects the expression of HMGCR mRNA Lovastatin results in increased expression of HMGCR mRNA |
CTD |
PMID:8517861 PMID:8593127 PMID:17208200 PMID:19260826 PMID:19699819 PMID:19856009 PMID:27208389 PMID:29852127 More...
|
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of HMGCS1 mRNA |
CTD |
PMID:29852127 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO |
Lovastatin results in increased expression of HMOX1 protein Lovastatin inhibits the reaction [Doxorubicin results in increased expression of HMOX1 mRNA] |
CTD |
PMID:20594940 PMID:21910007 PMID:28710503 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnrnpab |
heterogeneous nuclear ribonucleoprotein A/B |
increases expression |
ISO |
Lovastatin results in increased expression of HNRNPAB mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:35,857,040...35,862,935
Ensembl chr10:35,857,041...35,863,344
|
|
G |
Hnrnpdl |
heterogeneous nuclear ribonucleoprotein D-like |
decreases expression |
ISO |
Lovastatin results in decreased expression of HNRNPDL mRNA |
CTD |
PMID:20493250 |
|
NCBI chr14:9,557,430...9,563,659
Ensembl chr14:9,557,425...9,562,506
|
|
G |
Hnrnpf |
heterogeneous nuclear ribonucleoprotein F |
increases expression |
ISO |
Lovastatin results in increased expression of HNRNPF mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 4:151,083,262...151,104,464
Ensembl chr 4:151,083,062...151,109,038
|
|
G |
Hnrnpk |
heterogeneous nuclear ribonucleoprotein K |
decreases expression increases expression |
ISO |
Lovastatin results in decreased expression of HNRNPK mRNA Lovastatin results in increased expression of HNRNPK mRNA |
CTD |
PMID:20493250 |
|
NCBI chr17:6,262,936...6,275,001
Ensembl chr17:6,262,998...6,274,997
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
decreases prenylation multiple interactions |
ISO |
Lovastatin results in decreased prenylation of HRAS protein Lovastatin results in decreased prenylation of and results in decreased localization of HRAS protein |
CTD |
PMID:16156861 PMID:19360310 |
|
NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
|
|
G |
Hsp90ab1 |
heat shock protein 90 alpha family class B member 1 |
decreases expression |
ISO |
Lovastatin results in decreased expression of HSP90AB1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 9:15,432,986...15,438,358
Ensembl chr 9:15,433,691...15,438,488
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
increases expression |
ISO |
Lovastatin results in increased expression of HSPA8 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
increases expression |
ISO |
Lovastatin results in increased expression of HSPD1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 9:56,579,195...56,590,011
Ensembl chr 9:56,579,201...56,589,662
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA] |
CTD |
PMID:17507688 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igf1 |
insulin-like growth factor 1 |
decreases response to substance |
ISO |
IGF1 protein results in decreased susceptibility to Lovastatin |
CTD |
PMID:9525472 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
multiple interactions |
EXP |
Lovastatin promotes the reaction [INS protein results in increased phosphorylation of IGF1R protein] |
CTD |
PMID:19741129 |
|
NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
ISO |
[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein; geraniol inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]; geraniol promotes the reaction [lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]]; geraniol promotes the reaction [manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]]; geraniol promotes the reaction [tipifarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]]; lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]; manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]; tipifarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein] |
CTD |
PMID:21430599 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein; geraniol inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]; geraniol promotes the reaction [lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]]; geraniol promotes the reaction [manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]]; geraniol promotes the reaction [tipifarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]]; lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]; Lovastatin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]; tipifarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein] |
CTD |
PMID:18809656 PMID:21430599 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO EXP |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of IL6 mRNA] Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of IL6 protein] |
CTD |
PMID:28710503 PMID:35734936 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
EXP |
Lovastatin promotes the reaction [INS protein results in increased phosphorylation of IGF1R protein]; Lovastatin promotes the reaction [INS protein results in increased phosphorylation of INSR protein] |
CTD |
PMID:19741129 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Insig1 |
insulin induced gene 1 |
increases expression multiple interactions |
ISO |
Lovastatin results in increased expression of INSIG1 mRNA [Dietary Fats co-treated with Lovastatin] affects the expression of INSIG1 mRNA |
CTD |
PMID:19260826 PMID:29852127 |
|
NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952
|
|
G |
Insig2 |
insulin induced gene 2 |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of INSIG2 mRNA |
CTD |
PMID:29852127 |
|
NCBI chr13:32,472,390...32,500,139
Ensembl chr13:32,473,742...32,494,923
|
|
G |
Insr |
insulin receptor |
multiple interactions |
EXP |
Lovastatin promotes the reaction [INS protein results in increased phosphorylation of INSR protein] |
CTD |
PMID:19741129 |
|
NCBI chr12:1,193,193...1,330,976
Ensembl chr12:1,197,100...1,330,883
|
|
G |
Ipo5 |
importin 5 |
decreases expression |
ISO |
Lovastatin results in decreased expression of IPO5 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr15:97,990,755...98,041,074
Ensembl chr15:98,005,299...98,041,126
|
|
G |
Irf4 |
interferon regulatory factor 4 |
decreases expression |
ISO |
Lovastatin results in decreased expression of IRF4 protein |
CTD |
PMID:33034787 |
|
NCBI chr17:33,721,800...33,742,570
Ensembl chr17:33,721,811...33,740,070
|
|
G |
Irs1 |
insulin receptor substrate 1 |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of IRS1 mRNA |
CTD |
PMID:29852127 |
|
NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122
|
|
G |
Irs2 |
insulin receptor substrate 2 |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of IRS2 mRNA |
CTD |
PMID:29852127 |
|
NCBI chr16:78,488,249...78,512,482
Ensembl chr16:78,485,045...78,512,482
|
|
G |
Isyna1 |
inositol-3-phosphate synthase 1 |
increases expression |
ISO |
Lovastatin results in increased expression of ISYNA1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr16:18,839,143...18,841,979
Ensembl chr16:18,839,145...18,841,979
|
|
G |
Itgb1 |
integrin subunit beta 1 |
decreases expression |
ISO |
Lovastatin results in decreased expression of ITGB1 protein |
CTD |
PMID:12405293 |
|
NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
affects expression multiple interactions decreases expression |
EXP ISO |
Lovastatin affects the expression of JUN protein Lovastatin inhibits the reaction [Doxorubicin results in increased expression of JUN mRNA] Lovastatin results in decreased expression of JUN |
CTD |
PMID:10412747 PMID:12392621 PMID:22712078 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
affects activity |
ISO |
Lovastatin affects the activity of KCNH2 protein |
CTD |
PMID:16278312 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kcnj11 |
potassium inwardly-rectifying channel, subfamily J, member 11 |
increases expression |
ISO |
Lovastatin results in increased expression of KCNJ11 mRNA |
CTD |
PMID:38432573 |
|
NCBI chr 1:96,591,048...96,594,574
Ensembl chr 1:96,591,049...96,594,082
|
|
G |
Kras |
KRAS proto-oncogene, GTPase |
decreases prenylation increases expression affects localization increases activity |
ISO |
Lovastatin results in decreased prenylation of KRAS protein Lovastatin results in increased expression of KRAS protein Lovastatin affects the localization of KRAS protein Lovastatin results in increased activity of KRAS protein |
CTD |
PMID:12106604 PMID:12907238 PMID:16156861 PMID:17005160 |
|
NCBI chr 4:178,185,418...178,218,484
|
|
G |
Krt18 |
keratin 18 |
decreases expression |
ISO |
Lovastatin results in decreased expression of KRT18 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 7:133,157,486...133,161,162
Ensembl chr 7:133,157,475...133,161,166
|
|
G |
Lasp1 |
LIM and SH3 protein 1 |
decreases expression |
ISO |
Lovastatin results in decreased expression of LASP1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:82,795,177...82,835,659
Ensembl chr10:82,795,137...82,943,292
|
|
G |
Lcn2 |
lipocalin 2 |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of LCN2 mRNA |
CTD |
PMID:30853469 |
|
NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Ldha |
lactate dehydrogenase A |
increases expression |
ISO |
Lovastatin results in increased expression of LDHA protein |
CTD |
PMID:38432573 |
|
NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions increases activity increases expression |
ISO EXP |
OSM protein promotes the reaction [Lovastatin results in increased expression of LDLR mRNA] [Dietary Fats co-treated with Lovastatin] affects the expression of LDLR mRNA [Cholesterol deficiency co-treated with Lovastatin] results in increased expression of LDLR mRNA; Cholesterol inhibits the reaction [[Cholesterol deficiency co-treated with Lovastatin] results in increased expression of LDLR mRNA] Lovastatin results in increased activity of LDLR protein |
CTD |
PMID:8593127 PMID:11728391 PMID:12524230 PMID:20578043 PMID:29852127 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lef1 |
lymphoid enhancer binding factor 1 |
affects localization |
ISO |
Lovastatin affects the localization of LEF1 protein |
CTD |
PMID:17234346 |
|
NCBI chr 2:219,666,549...219,779,815
Ensembl chr 2:219,666,592...219,779,794
|
|
G |
Lipc |
lipase C, hepatic type |
affects expression |
ISO |
Lovastatin affects the expression of LIPC mRNA |
CTD |
PMID:27208389 |
|
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
|
|
G |
Lmnb1 |
lamin B1 |
decreases farnesylation increases degradation affects localization |
ISO |
Lovastatin results in decreased farnesylation of LMNB1 protein Lovastatin results in increased degradation of LMNB1 protein Lovastatin affects the localization of LMNB1 protein |
CTD |
PMID:10203554 PMID:11720884 |
|
NCBI chr18:50,175,861...50,215,210
Ensembl chr18:50,175,874...50,214,502
|
|
G |
Lpin2 |
lipin 2 |
decreases response to substance |
ISO |
LPIN2 SNP results in decreased susceptibility to Lovastatin |
CTD |
PMID:21483694 |
|
NCBI chr 9:111,083,378...111,158,193
Ensembl chr 9:111,083,745...111,158,193
|
|
G |
Lpl |
lipoprotein lipase |
affects expression multiple interactions |
ISO |
Lovastatin affects the expression of LPL mRNA [Dietary Fats co-treated with Lovastatin] affects the expression of LPL mRNA |
CTD |
PMID:27208389 PMID:29852127 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Lrp5 |
LDL receptor related protein 5 |
increases expression |
ISO |
Lovastatin results in increased expression of LRP5 mRNA |
CTD |
PMID:24742230 |
|
NCBI chr 1:200,814,247...200,917,581
Ensembl chr 1:200,814,250...200,917,581
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases expression increases phosphorylation decreases activity decreases phosphorylation |
EXP ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lovastatin results in decreased phosphorylation of MAPK1 protein]; 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide inhibits the reaction [Lovastatin results in decreased phosphorylation of MAPK1 protein]; Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased phosphorylation of MAPK1 protein]; Lovastatin inhibits the reaction [Phenylephrine results in increased phosphorylation of MAPK1 protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in decreased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Lovastatin results in increased phosphorylation of MAPK1 protein] Lovastatin results in increased expression of MAPK1 protein Lovastatin results in decreased activity of MAPK1 protein [Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK1 protein; Lovastatin affects the reaction [[MAPK1 protein co-treated with APP protein] affects the expression of APP protein]; Lovastatin affects the reaction [[MAPK1 protein co-treated with APP protein] affects the expression of CHRNA7 protein]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [[Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:12213976 PMID:16952276 PMID:19360310 PMID:19760159 PMID:20578043 PMID:24718106 PMID:29341888 PMID:38432573 More...
|
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
increases expression |
ISO |
Lovastatin results in increased expression of MAPK14 protein |
CTD |
PMID:38432573 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases expression increases phosphorylation decreases activity decreases phosphorylation |
ISO EXP |
[Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK3 protein; Lovastatin affects the reaction [[MAPK3 protein co-treated with APP protein] affects the expression of APP protein]; Lovastatin affects the reaction [[MAPK3 protein co-treated with APP protein] affects the expression of CHRNA7 protein]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [[Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK3 protein] Lovastatin results in increased expression of MAPK3 protein Lovastatin results in increased phosphorylation of MAPK3 protein Lovastatin results in decreased activity of MAPK3 protein Lovastatin results in decreased phosphorylation of MAPK3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lovastatin results in decreased phosphorylation of MAPK3 protein]; 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide inhibits the reaction [Lovastatin results in decreased phosphorylation of MAPK3 protein]; Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased phosphorylation of MAPK3 protein]; Lovastatin inhibits the reaction [benserazide, levodopa drug combination results in increased phosphorylation of MAPK3 protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in decreased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Lovastatin results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:16952276 PMID:18434508 PMID:19360310 PMID:19760159 PMID:20578043 PMID:24718106 PMID:29341888 PMID:38432573 More...
|
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [Cisplatin results in increased expression of MAPK8 protein modified form] |
CTD |
PMID:26739623 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [Cisplatin results in increased expression of MAPK9 protein modified form] |
CTD |
PMID:26739623 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mbp |
myelin basic protein |
multiple interactions increases expression |
EXP |
2-chloro-5-nitrobenzanilide inhibits the reaction [Lovastatin results in increased expression of MBP mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of MBP mRNA]; PPARG protein affects the reaction [Lovastatin results in increased expression of MBP mRNA]; PTEN protein affects the reaction [Lovastatin results in increased expression of MBP mRNA] |
CTD |
PMID:20578043 |
|
NCBI chr18:75,855,878...75,966,404
Ensembl chr18:75,855,878...75,966,404
|
|
G |
Mfn2 |
mitofusin 2 |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of MFN2 mRNA] |
CTD |
PMID:28710503 |
|
NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342
|
|
G |
Mir133b |
microRNA 133b |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of MIR133B mRNA |
CTD |
PMID:30853469 |
|
NCBI chr 9:23,098,134...23,098,217
Ensembl chr 9:23,098,134...23,098,217
|
|
G |
Mir206 |
microRNA 206 |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of MIR206 mRNA |
CTD |
PMID:30853469 |
|
NCBI chr 9:23,094,249...23,094,332
Ensembl chr 9:23,094,249...23,094,332
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases expression |
ISO |
Lovastatin results in decreased expression of MMP2 protein |
CTD |
PMID:19360310 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of MMP3 mRNA] |
CTD |
PMID:28710503 |
|
NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases expression |
ISO |
Lovastatin results in decreased expression of MMP9 protein |
CTD |
PMID:19360310 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of MPO protein] |
CTD |
PMID:35734936 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mstn |
myostatin |
increases expression |
ISO |
Lovastatin results in increased expression of MSTN protein |
CTD |
PMID:33034787 |
|
NCBI chr 9:48,452,533...48,458,933
Ensembl chr 9:48,452,533...48,458,933
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
Doxorubicin inhibits the reaction [Lovastatin results in increased expression of NFE2L2 mRNA]; Lovastatin inhibits the reaction [Doxorubicin results in increased expression of NFE2L2 mRNA] |
CTD |
PMID:22712078 PMID:28710503 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nmral1 |
NmrA like redox sensor 1 |
increases expression |
ISO |
Lovastatin results in increased expression of NMRAL1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:10,841,693...10,850,199
Ensembl chr10:10,841,799...10,850,192
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO EXP |
Lovastatin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA] Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of NOS2 protein] |
CTD |
PMID:18809656 PMID:35734936 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of NPPA mRNA] |
CTD |
PMID:28710503 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
ISO |
Lovastatin results in increased expression of NQO1 mRNA |
CTD |
PMID:1311272 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
[Lovastatin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA |
CTD |
PMID:17041008 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nras |
NRAS proto-oncogene, GTPase |
decreases prenylation |
ISO |
Lovastatin results in decreased prenylation of NRAS protein |
CTD |
PMID:16156861 |
|
NCBI chr 2:190,582,885...190,593,509
Ensembl chr 2:190,582,918...190,591,626
|
|
G |
Nucb1 |
nucleobindin 1 |
increases expression |
ISO |
Lovastatin results in increased expression of NUCB1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:95,968,325...95,999,183
Ensembl chr 1:95,968,326...96,003,220
|
|
G |
Oat |
ornithine aminotransferase |
decreases expression |
ISO |
Lovastatin results in decreased expression of OAT mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:187,347,862...187,367,644
Ensembl chr 1:187,347,865...187,367,682
|
|
G |
Osm |
oncostatin M |
multiple interactions |
ISO |
OSM protein promotes the reaction [Lovastatin results in increased expression of LDLR mRNA] |
CTD |
PMID:12524230 |
|
NCBI chr14:79,103,638...79,108,500
Ensembl chr14:79,104,344...79,108,313
|
|
G |
Pa2g4 |
proliferation-associated 2G4 |
increases expression |
ISO |
Lovastatin results in increased expression of PA2G4 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 7:984,795...992,264
Ensembl chr 7:983,971...992,331
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
Lovastatin analog results in increased cleavage of PARP1 protein |
CTD |
PMID:26863638 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Parvb |
parvin, beta |
decreases response to substance |
ISO |
PARVB SNP results in decreased susceptibility to Lovastatin |
CTD |
PMID:21483694 |
|
NCBI chr 7:115,360,254...115,445,767
Ensembl chr 7:115,360,261...115,445,766
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of PCK1 mRNA |
CTD |
PMID:29852127 |
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Pdgfra |
platelet derived growth factor receptor alpha |
decreases expression |
EXP |
Lovastatin results in decreased expression of PDGFRA mRNA |
CTD |
PMID:20578043 |
|
NCBI chr14:33,005,838...33,054,347
Ensembl chr14:33,005,839...33,054,335
|
|
G |
Pdia3 |
protein disulfide isomerase family A, member 3 |
decreases expression increases expression |
ISO |
Lovastatin results in decreased expression of PDIA3 mRNA Lovastatin results in increased expression of PDIA3 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 3:108,388,189...108,412,013
Ensembl chr 3:108,388,245...108,413,236
|
|
G |
Pdia4 |
protein disulfide isomerase family A, member 4 |
decreases expression |
ISO |
Lovastatin results in decreased expression of PDIA4 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 4:76,803,198...76,822,245
Ensembl chr 4:76,803,198...76,822,107
|
|
G |
Pgam1 |
phosphoglycerate mutase 1 |
decreases expression increases expression |
ISO |
Lovastatin results in decreased expression of PGAM1 mRNA Lovastatin results in increased expression of PGAM1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:240,723,832...240,731,443
Ensembl chr 1:240,723,920...240,738,452
|
|
G |
Pkm |
pyruvate kinase M1/2 |
decreases expression |
ISO |
Lovastatin results in decreased expression of PKM mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 8:60,057,629...60,079,600
Ensembl chr 8:60,057,402...60,079,599
|
|
G |
Pla2g4a |
phospholipase A2 group 4A |
increases expression |
EXP |
Lovastatin results in increased expression of PLA2G4A mRNA |
CTD |
PMID:20578043 |
|
NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266
|
|
G |
Plat |
plasminogen activator, tissue type |
multiple interactions increases secretion increases expression |
EXP ISO |
geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of PLAT protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in increased expression of PLAT protein] Lovastatin results in increased secretion of PLAT protein |
CTD |
PMID:10412747 PMID:12405293 |
|
NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223
|
|
G |
Plau |
plasminogen activator, urokinase |
decreases secretion |
ISO |
Lovastatin results in decreased secretion of PLAU protein |
CTD |
PMID:12405293 |
|
NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
|
|
G |
Pon3 |
paraoxonase 3 |
increases hydrolysis increases metabolic processing multiple interactions |
ISO |
PON3 protein results in increased hydrolysis of Lovastatin PON3 protein results in increased metabolism of Lovastatin 7-ketocholesterol inhibits the reaction [PON3 protein results in increased metabolism of Lovastatin]; Phosphatidylcholines inhibits the reaction [PON3 protein results in increased metabolism of Lovastatin] |
CTD |
PMID:12615656 PMID:15772423 |
|
NCBI chr 4:33,356,983...33,383,681
Ensembl chr 4:33,349,168...33,383,855
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions affects localization increases expression |
ISO EXP |
2-chloro-5-nitrobenzanilide inhibits the reaction [Lovastatin analog affects the localization of PPARG protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Lovastatin analog affects the localization of PPARG protein]; PPARG protein affects the reaction [Lovastatin results in increased expression of PTEN protein] geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of PPARG mRNA]; Lovastatin results in increased expression of and affects the localization of PPARG protein; Mevalonic Acid inhibits the reaction [Lovastatin results in increased expression of PPARG mRNA]; PPARG protein affects the reaction [Lovastatin results in increased expression of MBP mRNA]; PPARG protein affects the reaction [Lovastatin results in increased expression of SOX10 mRNA] [Dietary Fats co-treated with Lovastatin] affects the expression of PPARG mRNA; PPARG affects the reaction [Lovastatin results in increased expression of PTEN protein] |
CTD |
PMID:16425225 PMID:20578043 PMID:26863638 PMID:29852127 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of PPARGC1A mRNA] |
CTD |
PMID:28710503 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ppp1ca |
protein phosphatase 1 catalytic subunit alpha |
decreases expression |
ISO |
Lovastatin results in decreased expression of PPP1CA mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:201,485,117...201,488,734
Ensembl chr 1:201,485,085...201,497,327
|
|
G |
Ppp2r1a |
protein phosphatase 2 scaffold subunit A alpha |
increases expression |
ISO |
Lovastatin results in increased expression of PPP2R1A mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:60,540,223...60,559,467
Ensembl chr 1:60,540,194...60,560,129
|
|
G |
Prg4 |
proteoglycan 4 |
increases expression |
ISO |
Lovastatin results in increased expression of PRG4 mRNA; Lovastatin results in increased expression of PRG4 protein |
CTD |
PMID:38432573 |
|
NCBI chr13:62,487,257...62,504,657
Ensembl chr13:62,487,257...62,504,119
|
|
G |
Prkca |
protein kinase C, alpha |
increases expression |
ISO |
Lovastatin results in increased expression of PRKCA protein |
CTD |
PMID:38432573 |
|
NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012
|
|
G |
Prkcd |
protein kinase C, delta |
multiple interactions increases cleavage |
EXP |
benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [Lovastatin results in increased cleavage of PRKCD protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in increased cleavage of PRKCD protein] |
CTD |
PMID:16367743 |
|
NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352
|
|
G |
Psma3 |
proteasome 20S subunit alpha 3 |
decreases expression |
ISO |
Lovastatin results in decreased expression of PSMA3 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 6:89,483,741...89,503,775
Ensembl chr 6:89,483,727...89,504,965
|
|
G |
Psma6 |
proteasome 20S subunit alpha 6 |
decreases expression |
ISO |
Lovastatin results in decreased expression of PSMA6 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 6:72,765,534...72,796,554
Ensembl chr 6:72,765,473...72,796,554
|
|
G |
Psmc2 |
proteasome 26S subunit, ATPase 2 |
decreases expression |
ISO |
Lovastatin results in decreased expression of PSMC2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 4:13,255,850...13,270,160
Ensembl chr 4:13,255,856...13,270,185
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions increases expression |
ISO EXP |
Cycloheximide inhibits the reaction [Lovastatin results in increased expression of PTEN protein]; PPARG protein affects the reaction [Lovastatin results in increased expression of PTEN protein] 2-chloro-5-nitrobenzanilide inhibits the reaction [Lovastatin results in increased expression of PTEN mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of PTEN mRNA]; Lovastatin results in increased expression of and results in increased phosphorylation of PTEN protein; PTEN protein affects the reaction [Lovastatin results in increased expression of MBP mRNA]; PTEN protein affects the reaction [Lovastatin results in increased expression of SOX10 mRNA] PPARG affects the reaction [Lovastatin results in increased expression of PTEN protein] |
CTD |
PMID:16425225 PMID:20578043 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression increases expression multiple interactions |
ISO EXP |
Lovastatin results in decreased expression of PTGS2 protein Lovastatin analog results in increased expression of PTGS2 mRNA; Lovastatin analog results in increased expression of PTGS2 protein Mevalonic Acid affects the reaction [Lovastatin analog results in increased expression of PTGS2 protein] Lovastatin results in increased expression of PTGS2 mRNA; Lovastatin results in increased expression of PTGS2 protein |
CTD |
PMID:20578043 PMID:21910007 PMID:26863638 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rab1a |
RAB1A, member RAS oncogene family |
decreases expression |
ISO |
Lovastatin results in decreased expression of RAB1A mRNA |
CTD |
PMID:20493250 |
|
NCBI chr14:94,422,219...94,448,799
Ensembl chr14:94,415,275...94,448,248
|
|
G |
Rac1 |
Rac family small GTPase 1 |
multiple interactions affects localization decreases activity increases expression |
ISO |
geranylgeraniol inhibits the reaction [Lovastatin affects the localization of RAC1 protein]; Mevalonic Acid inhibits the reaction [Lovastatin affects the localization of RAC1 protein] Lovastatin results in decreased activity of RAC1 protein Lovastatin results in increased expression of RAC1 protein |
CTD |
PMID:12933658 PMID:18766339 PMID:19360310 PMID:21356574 |
|
NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
multiple interactions decreases activity |
ISO |
Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of RAF1 protein] Lovastatin results in decreased activity of RAF1 protein |
CTD |
PMID:19360310 PMID:19760159 |
|
NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317
|
|
G |
Rap1a |
RAP1A, member of RAS oncogene family |
increases expression |
ISO |
Lovastatin results in increased expression of RAP1A protein |
CTD |
PMID:12467231 |
|
NCBI chr 2:193,208,631...193,286,513
Ensembl chr 2:193,208,635...193,286,501
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases phosphorylation |
EXP ISO |
Lovastatin results in decreased phosphorylation of RB1 protein |
CTD |
PMID:9848777 PMID:10502407 PMID:15118409 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rhoa |
ras homolog family member A |
multiple interactions decreases expression decreases prenylation affects localization |
ISO EXP |
geranylgeraniol inhibits the reaction [Lovastatin affects the localization of RHOA protein]; Mevalonic Acid inhibits the reaction [Lovastatin affects the localization of RHOA protein] Lovastatin results in decreased geranoylation of and affects the localization of RHOA protein Lovastatin results in decreased expression of RHOA mRNA Lovastatin results in decreased prenylation of RHOA protein Farnesol inhibits the reaction [Lovastatin affects the localization of RHOA protein]; geranylgeraniol inhibits the reaction [Lovastatin affects the localization of RHOA protein] |
CTD |
PMID:9398081 PMID:11178870 PMID:12405293 PMID:12933658 PMID:16156861 PMID:20493250 PMID:20578043 More...
|
|
NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Rhob |
ras homolog family member B |
decreases prenylation multiple interactions increases expression |
ISO |
Lovastatin results in decreased prenylation of RHOB protein Lovastatin promotes the reaction [RHOB protein binds to CASP2 protein] Lovastatin results in increased expression of RHOB protein |
CTD |
PMID:12467231 PMID:16156861 PMID:16234849 |
|
NCBI chr 6:31,363,752...31,365,926
Ensembl chr 6:31,363,548...31,366,108
|
|
G |
Rpl27 |
ribosomal protein L27 |
increases expression |
ISO |
Lovastatin results in increased expression of RPL27 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:86,375,511...86,379,210
Ensembl chr10:86,375,454...86,379,193
|
|
G |
Rpl9 |
ribosomal protein L9 |
increases expression |
ISO |
Lovastatin results in increased expression of RPL9 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr14:42,893,945...42,897,140
Ensembl chr14:42,893,942...42,897,136 Ensembl chr 3:42,893,942...42,897,136
|
|
G |
Rplp0 |
ribosomal protein lateral stalk subunit P0 |
increases expression |
ISO |
Lovastatin results in increased expression of RPLP0 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr12:41,054,363...41,057,632
Ensembl chr12:41,054,179...41,057,632
|
|
G |
Rpsa |
ribosomal protein SA |
increases expression |
ISO |
Lovastatin results in increased expression of RPSA mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 8:119,851,225...119,855,103
Ensembl chr 8:119,851,225...119,855,247
|
|
G |
Ruvbl2 |
RuvB-like AAA ATPase 2 |
decreases expression |
ISO |
Lovastatin results in decreased expression of RUVBL2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:95,902,014...95,915,247
Ensembl chr 1:95,901,701...95,915,342
|
|
G |
S100a8 |
S100 calcium binding protein A8 |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of S100A8 mRNA |
CTD |
PMID:30853469 |
|
NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643
|
|
G |
S100a9 |
S100 calcium binding protein A9 |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of S100A9 mRNA |
CTD |
PMID:30853469 |
|
NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230
|
|
G |
Sae1 |
SUMO1 activating enzyme subunit 1 |
decreases expression |
ISO |
Lovastatin results in decreased expression of SAE1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:77,030,961...77,086,937
Ensembl chr 1:77,030,965...77,086,986
|
|
G |
Scap |
SREBF chaperone |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of SCAP mRNA |
CTD |
PMID:29852127 |
|
NCBI chr 8:110,306,026...110,360,677
Ensembl chr 8:110,306,031...110,360,666
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
multiple interactions affects expression |
ISO |
[Chloroquine co-treated with Lovastatin] inhibits the reaction [SCARB1 protein results in increased abundance of Progesterone] Lovastatin affects the expression of SCARB1 mRNA |
CTD |
PMID:20404351 PMID:27208389 |
|
NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of SCD1 mRNA |
CTD |
PMID:29852127 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Sephs1 |
selenophosphate synthetase 1 |
increases expression |
ISO |
Lovastatin results in increased expression of SEPHS1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr17:73,354,435...73,382,803
Ensembl chr17:73,356,530...73,382,593
|
|
G |
Slc31a1 |
solute carrier family 31 member 1 |
increases expression |
EXP |
Lovastatin results in increased expression of SLC31A1 mRNA |
CTD |
PMID:26739623 |
|
NCBI chr 5:75,814,744...75,844,241
Ensembl chr 5:75,814,743...75,844,228
|
|
G |
Sox10 |
SRY-box transcription factor 10 |
multiple interactions increases expression |
EXP |
geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of SOX10 mRNA]; PPARG protein affects the reaction [Lovastatin results in increased expression of SOX10 mRNA]; PTEN protein affects the reaction [Lovastatin results in increased expression of SOX10 mRNA] |
CTD |
PMID:20578043 |
|
NCBI chr 7:110,725,274...110,734,651
Ensembl chr 7:110,725,274...110,735,544
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions increases expression |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of SREBF1 mRNA Lovastatin results in increased expression of SREBF1 mRNA |
CTD |
PMID:29852127 PMID:32739440 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Srebf2 |
sterol regulatory element binding transcription factor 2 |
increases localization multiple interactions |
ISO EXP |
Lovastatin results in increased localization of SREBF2 protein [Dietary Fats co-treated with Lovastatin] affects the expression of SREBF2 mRNA [Cholesterol deficiency co-treated with Lovastatin] results in increased activity of SREBF2 protein; Cholesterol inhibits the reaction [[Cholesterol deficiency co-treated with Lovastatin] results in increased activity of SREBF2 protein] |
CTD |
PMID:11728391 PMID:20578043 PMID:29852127 |
|
NCBI chr 7:113,663,202...113,720,850
Ensembl chr 7:113,663,202...113,720,848
|
|
G |
Steap2 |
STEAP2 metalloreductase |
decreases response to substance |
ISO |
STEAP2 SNP results in decreased susceptibility to Lovastatin |
CTD |
PMID:21483694 |
|
NCBI chr 4:28,347,769...28,368,177
Ensembl chr 4:28,348,362...28,375,791
|
|
G |
Stip1 |
stress-induced phosphoprotein 1 |
decreases expression |
ISO |
Lovastatin results in decreased expression of STIP1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:204,209,433...204,228,452
Ensembl chr 1:204,178,932...204,228,476
|
|
G |
Syngap1 |
synaptic Ras GTPase activating protein 1 |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of SYNGAP1 protein] |
CTD |
PMID:24718106 |
|
NCBI chr20:5,026,366...5,056,659
Ensembl chr20:5,026,364...5,056,672
|
|
G |
Tcp1 |
t-complex 1 |
increases expression |
ISO |
Lovastatin results in increased expression of TCP1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:47,829,061...47,836,809
Ensembl chr 1:47,828,652...47,836,839
|
|
G |
Tg |
thyroglobulin |
increases secretion |
ISO |
Lovastatin results in increased secretion of TG protein |
CTD |
PMID:12843138 |
|
NCBI chr 7:98,418,293...98,603,210
Ensembl chr 7:98,418,293...98,603,210
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [TGFB1 protein results in increased abundance of Reactive Oxygen Species]; Lovastatin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] |
CTD |
PMID:22129737 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Th |
tyrosine hydroxylase |
increases expression multiple interactions |
ISO |
Lovastatin results in increased expression of TH protein Mevalonic Acid inhibits the reaction [Lovastatin results in increased expression of TH protein] |
CTD |
PMID:20694854 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Thop1 |
thimet oligopeptidase 1 |
increases expression |
ISO |
Lovastatin results in increased expression of THOP1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 7:8,632,911...8,645,339
Ensembl chr 7:8,632,916...8,645,275
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein; geraniol inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein]; geraniol promotes the reaction [lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein]]; geraniol promotes the reaction [manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein]]; geraniol promotes the reaction [tipifarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein]]; lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein]; Lovastatin inhibits the reaction [Doxorubicin results in increased expression of TNF mRNA]; Lovastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Lovastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein] Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of TNF protein] |
CTD |
PMID:18809656 PMID:21430599 PMID:22712078 PMID:35734936 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
increases expression |
ISO |
Lovastatin results in increased expression of TNFRSF11B mRNA |
CTD |
PMID:24742230 |
|
NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
increases response to substance |
ISO |
Lovastatin results in increased susceptibility to TNFSF10 protein |
CTD |
PMID:17928957 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
decreases expression |
ISO |
Lovastatin results in decreased expression of TNFSF11 mRNA |
CTD |
PMID:24742230 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Top2a |
DNA topoisomerase II alpha |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of TOP2A mRNA] |
CTD |
PMID:22712078 |
|
NCBI chr10:83,945,731...83,976,874
Ensembl chr10:83,945,735...83,976,874
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases expression |
ISO EXP |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]; Lovastatin results in increased expression of and results in increased phosphorylation of TP53 protein Lovastatin inhibits the reaction [Cisplatin results in increased expression of TP53 protein modified form] Lovastatin results in increased expression of TP53 mRNA |
CTD |
PMID:17088865 PMID:21199873 PMID:26739623 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Trim63 |
tripartite motif containing 63 |
multiple interactions |
ISO |
Lovastatin promotes the reaction [Fenofibrate results in increased expression of TRIM63 protein] |
CTD |
PMID:33408297 |
|
NCBI chr 5:146,533,492...146,547,332
Ensembl chr 5:146,533,507...146,547,322
|
|
G |
Ttc7a |
tetratricopeptide repeat domain 7A |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of FSN mRNA |
CTD |
PMID:29852127 |
|
NCBI chr 6:7,159,285...7,261,826
Ensembl chr 6:7,159,061...7,261,892
|
|
G |
Tuba1a |
tubulin, alpha 1A |
increases expression |
ISO |
Lovastatin results in increased expression of TUBA1A mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 7:130,113,214...130,116,880
Ensembl chr 7:130,081,032...130,196,186
|
|
G |
Tuba1b |
tubulin, alpha 1B |
increases expression decreases expression |
ISO |
Lovastatin results in increased expression of TUBA1B mRNA Lovastatin results in decreased expression of TUBA1B mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 7:130,090,663...130,093,644
Ensembl chr 7:130,081,032...130,196,186
|
|
G |
Tubb5 |
tubulin, beta 5 class I |
decreases expression |
ISO |
Lovastatin results in decreased expression of TUBB5 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr20:2,912,779...2,916,928
Ensembl chr20:2,912,778...2,916,940
|
|
G |
Tufm |
Tu translation elongation factor, mitochondrial |
decreases expression |
ISO |
Lovastatin results in decreased expression of TUFM mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:181,073,788...181,077,395
Ensembl chr 1:181,073,788...181,077,395
|
|
G |
U2af2 |
U2 small nuclear RNA auxiliary factor 2 |
increases expression |
ISO |
Lovastatin results in increased expression of U2AF2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:68,760,911...68,779,730
Ensembl chr 1:68,760,924...68,778,492
|
|
G |
Ucp2 |
uncoupling protein 2 |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of UCP2 mRNA |
CTD |
PMID:29852127 |
|
NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
|
|
G |
Usp5 |
ubiquitin specific peptidase 5 |
decreases expression |
ISO |
Lovastatin results in decreased expression of USP5 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 4:157,619,663...157,634,681
Ensembl chr 4:157,619,643...157,634,711
|
|
G |
Vcp |
valosin-containing protein |
decreases expression increases expression |
ISO |
Lovastatin results in decreased expression of VCP mRNA Lovastatin results in increased expression of VCP mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 5:57,210,167...57,229,571
Ensembl chr 5:57,210,168...57,229,571
|
|
G |
Wee1 |
WEE1 G2 checkpoint kinase |
multiple interactions increases expression |
ISO |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of WEE1 mRNA] Lovastatin results in increased expression of WEE1 mRNA |
CTD |
PMID:22712078 |
|
NCBI chr 1:164,173,681...164,197,688
Ensembl chr 1:164,174,779...164,197,688
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
increases expression |
EXP |
Lovastatin results in increased expression of XIAP mRNA |
CTD |
PMID:26739623 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|
G |
Xpa |
XPA, DNA damage recognition and repair factor |
increases expression |
EXP |
Lovastatin results in increased expression of XPA mRNA |
CTD |
PMID:26739623 |
|
NCBI chr 5:60,431,673...60,475,726
Ensembl chr 5:60,431,673...60,475,726
|
|
G |
Ywhae |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon |
increases expression |
ISO |
Lovastatin results in increased expression of YWHAE mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:60,584,665...60,622,352
Ensembl chr10:60,584,652...60,671,589
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
affects expression decreases expression multiple interactions |
EXP ISO |
mevastatin affects the expression of ABCA1 mRNA Mevastatin (compactin) decreases expression of abca1 mRNA in rat peripheral fibroblasts Mevalonic Acid inhibits the reaction [mevastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCA1 protein]] |
CTD RGD |
PMID:16415093 PMID:17526932 PMID:17526932 |
RGD:2308820 |
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
ISO |
mevastatin inhibits the reaction [BDNF protein results in decreased activity of HU 211] |
CTD |
PMID:20554863 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
increases expression |
ISO |
mevastatin results in increased expression of BMP2 mRNA; mevastatin results in increased expression of BMP2 protein |
CTD |
PMID:10814523 |
|
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Cd40 |
CD40 molecule |
multiple interactions |
ISO |
mevastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA] |
CTD |
PMID:17507688 |
|
NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions increases expression |
ISO |
[mevastatin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; NR1I2 protein promotes the reaction [mevastatin results in increased expression of CYP3A4 mRNA] |
CTD |
PMID:12235278 PMID:15466163 PMID:17041008 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions decreases expression |
ISO |
EIF2S1 protein modified form inhibits the reaction [mevastatin results in decreased expression of DDIT3 mRNA] |
CTD |
PMID:16330322 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
increases phosphorylation |
ISO |
mevastatin results in increased phosphorylation of EIF2AK3 protein |
CTD |
PMID:16330322 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
multiple interactions |
ISO |
EIF2S1 protein modified form inhibits the reaction [mevastatin results in decreased expression of DDIT3 mRNA]; EIF2S1 protein modified form inhibits the reaction [mevastatin results in increased cleavage of SREBF1 protein]; EIF2S1 protein modified form inhibits the reaction [mevastatin results in increased expression of IDI1 mRNA]; EIF2S1 protein modified form inhibits the reaction [mevastatin results in increased expression of MSMO1 mRNA] |
CTD |
PMID:16330322 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Foxo1 |
forkhead box O1 |
decreases phosphorylation |
ISO |
mevastatin results in decreased phosphorylation of FOXO1 protein |
CTD |
PMID:33034787 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Idi1 |
isopentenyl-diphosphate delta isomerase 1 |
multiple interactions increases expression |
ISO |
EIF2S1 protein modified form inhibits the reaction [mevastatin results in increased expression of IDI1 mRNA] |
CTD |
PMID:16330322 |
|
NCBI chr17:61,629,592...61,637,357
Ensembl chr17:61,629,594...61,637,357
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
mevastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA] |
CTD |
PMID:17507688 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
mevastatin promotes the reaction [IL1B protein results in increased expression of SELE protein] |
CTD |
PMID:10946302 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Irf4 |
interferon regulatory factor 4 |
decreases expression |
ISO |
mevastatin results in decreased expression of IRF4 protein |
CTD |
PMID:33034787 |
|
NCBI chr17:33,721,800...33,742,570
Ensembl chr17:33,721,811...33,740,070
|
|
G |
Msmo1 |
methylsterol monooxygenase 1 |
increases expression multiple interactions |
ISO |
mevastatin results in increased expression of MSMO1 mRNA EIF2S1 protein modified form inhibits the reaction [mevastatin results in increased expression of MSMO1 mRNA] |
CTD |
PMID:16330322 |
|
NCBI chr16:24,980,680...24,997,927
Ensembl chr16:24,980,697...24,998,016
|
|
G |
Mstn |
myostatin |
increases expression |
ISO |
mevastatin results in increased expression of MSTN protein |
CTD |
PMID:33034787 |
|
NCBI chr 9:48,452,533...48,458,933
Ensembl chr 9:48,452,533...48,458,933
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
increases expression |
ISO |
Mevastatin increases expression of NR1H3 mRNA in mononuclear cells |
RGD |
PMID:16252156 |
RGD:401827902 |
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
[mevastatin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; NR1I2 protein promotes the reaction [mevastatin results in increased expression of CYP3A4 mRNA] |
CTD |
PMID:12235278 PMID:17041008 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Rac1 |
Rac family small GTPase 1 |
multiple interactions |
ISO |
mevastatin results in increased abundance of [Guanosine Triphosphate binds to RAC1 protein] |
CTD |
PMID:16734383 |
|
NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251
|
|
G |
Rhoa |
ras homolog family member A |
decreases lipidation multiple interactions |
ISO |
mevastatin results in decreased lipidation of RHOA protein Mevalonic Acid inhibits the reaction [mevastatin results in decreased lipidation of RHOA protein] |
CTD |
PMID:17322126 |
|
NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Sele |
selectin E |
multiple interactions |
ISO |
mevastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]; mevastatin promotes the reaction [TNF protein results in increased expression of SELE protein] |
CTD |
PMID:10946302 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
decreases expression increases cleavage multiple interactions |
EXP ISO |
mevastatin results in decreased expression of SREBF1 protein mevastatin results in increased cleavage of SREBF1 protein EIF2S1 protein modified form inhibits the reaction [mevastatin results in increased cleavage of SREBF1 protein] |
CTD |
PMID:16330322 PMID:17526932 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Srebf2 |
sterol regulatory element binding transcription factor 2 |
increases expression increases cleavage |
EXP ISO |
mevastatin results in increased expression of SREBF2 protein mevastatin results in increased cleavage of SREBF2 protein |
CTD |
PMID:16330322 PMID:17526932 |
|
NCBI chr 7:113,663,202...113,720,850
Ensembl chr 7:113,663,202...113,720,848
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
mevastatin promotes the reaction [TNF protein results in increased expression of SELE protein] |
CTD |
PMID:10946302 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Xbp1 |
X-box binding protein 1 |
multiple interactions |
ISO |
Tunicamycin inhibits the reaction [mevastatin results in increased cleavage of XBP1 protein] |
CTD |
PMID:16330322 |
|
NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions increases expression |
ISO EXP |
GW 6471 inhibits the reaction [pitavastatin results in increased expression of ABCA1 mRNA]; PPARA protein affects the reaction [pitavastatin results in increased expression of ABCA1 mRNA] pitavastatin increases expression of ABCA1 mRNA in HepG2 cells pitavastatin increases expression of abca1 mRNA in rat liver pitavastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCA1 protein] |
CTD RGD |
PMID:16415093 PMID:21554872 PMID:21554872 PMID:21554872 |
RGD:21408554, RGD:21408554 |
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions decreases activity |
ISO |
pitavastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; pitavastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] pitavastatin results in decreased activity of ABCB11 protein |
CTD |
PMID:15901796 PMID:24014644 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
affects transport |
ISO |
ABCB1 protein affects the transport of pitavastatin |
CTD |
PMID:15955871 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
affects transport multiple interactions |
ISO EXP |
ABCC2 protein affects the transport of pitavastatin ABCC2 protein binds to and results in increased uptake of pitavastatin analog; pitavastatin analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein] |
CTD |
PMID:15955871 PMID:23562342 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
affects transport |
ISO |
ABCG2 protein affects the transport of pitavastatin |
CTD |
PMID:15955871 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions increases expression |
ISO |
EIF2AK3 protein affects the reaction [pitavastatin results in increased expression of ATF4 protein] |
CTD |
PMID:37956312 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
multiple interactions increases expression affects response to substance |
ISO |
BBC3 protein affects the susceptibility to [S63845 co-treated with pitavastatin]; BBC3 protein affects the susceptibility to [venetoclax co-treated with pitavastatin] pitavastatin results in increased expression of BBC3 mRNA; pitavastatin results in increased expression of BBC3 protein BBC3 protein affects the susceptibility to pitavastatin |
CTD |
PMID:37956312 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
pitavastatin inhibits the reaction [LEP gene mutant form results in increased expression of CCL2 mRNA]; pitavastatin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA] |
CTD |
PMID:18323514 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
ISO |
EIF2AK3 protein affects the reaction [pitavastatin results in increased expression of ATF4 protein] |
CTD |
PMID:37956312 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Foxo1 |
forkhead box O1 |
decreases phosphorylation |
ISO |
pitavastatin results in decreased phosphorylation of FOXO1 protein |
CTD |
PMID:33034787 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Ifnb1 |
interferon beta 1 |
multiple interactions |
ISO |
pitavastatin inhibits the reaction [Lipopolysaccharides results in increased expression of IFNB1 mRNA]; pitavastatin inhibits the reaction [Palmitic Acid results in increased expression of IFNB1 mRNA]; pitavastatin inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA] |
CTD |
PMID:18323514 |
|
NCBI chr 5:103,020,758...103,021,595
Ensembl chr 5:103,020,969...103,021,523
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
pitavastatin inhibits the reaction [LEP gene mutant form results in increased expression of IL6 mRNA]; pitavastatin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; pitavastatin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; pitavastatin inhibits the reaction [Palmitic Acid results in increased expression of IL6 mRNA]; pitavastatin inhibits the reaction [Poly I-C results in increased expression of IL6 mRNA] |
CTD |
PMID:18323514 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Irf3 |
interferon regulatory factor 3 |
multiple interactions |
ISO |
pitavastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of IRF3 protein]; pitavastatin inhibits the reaction [Palmitic Acid results in increased phosphorylation of IRF3 protein] |
CTD |
PMID:18323514 |
|
NCBI chr 1:95,479,966...95,484,926
Ensembl chr 1:95,479,821...95,484,935
|
|
G |
Irf4 |
interferon regulatory factor 4 |
decreases expression |
ISO |
pitavastatin results in decreased expression of IRF4 protein |
CTD |
PMID:33034787 |
|
NCBI chr17:33,721,800...33,742,570
Ensembl chr17:33,721,811...33,740,070
|
|
G |
Itgam |
integrin subunit alpha M |
increases expression |
ISO |
Pitavastatin increases expression of ITGAM protein in plasma |
RGD |
PMID:32310273 |
RGD:329853773 |
NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
pitavastatin inhibits the reaction [LEP gene mutant form results in increased expression of CCL2 mRNA]; pitavastatin inhibits the reaction [LEP gene mutant form results in increased expression of IL6 mRNA]; pitavastatin inhibits the reaction [LEP gene mutant form results in increased expression of TNF mRNA] |
CTD |
PMID:18323514 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Mstn |
myostatin |
increases expression |
ISO |
pitavastatin results in increased expression of MSTN protein |
CTD |
PMID:33034787 |
|
NCBI chr 9:48,452,533...48,458,933
Ensembl chr 9:48,452,533...48,458,933
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
pitavastatin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; pitavastatin inhibits the reaction [Palmitic Acid results in increased expression of NOS2 mRNA]; pitavastatin inhibits the reaction [Poly I-C results in increased expression of NOS2 mRNA] |
CTD |
PMID:18323514 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nr1h2 |
nuclear receptor subfamily 1, group H, member 2 |
multiple interactions |
ISO |
NR1H2 gene mutant form inhibits the reaction [pitavastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased export of Cholesterol]]; NR1H2 gene mutant form inhibits the reaction [pitavastatin results in decreased export of Cholesterol] |
CTD |
PMID:16415093 |
|
NCBI chr 1:95,041,967...95,047,358
Ensembl chr 1:95,041,967...95,047,377
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
multiple interactions |
ISO |
NR1H3 gene mutant form inhibits the reaction [pitavastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased export of Cholesterol]]; NR1H3 gene mutant form inhibits the reaction [pitavastatin results in decreased export of Cholesterol] |
CTD |
PMID:16415093 |
|
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
pitavastatin results in increased cleavage of PARP1 protein |
CTD |
PMID:37956312 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
increases expression multiple interactions |
ISO |
pitavastatin results in increased expression of PMAIP1 protein 2-(4-chlorophenoxy)-N-(4-(2-(4-chlorophenoxy)acetamido)cyclohexyl)acetamide inhibits the reaction [pitavastatin results in increased expression of PMAIP1 protein] |
CTD |
PMID:37956312 |
|
NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429
|
|
G |
Pon1 |
paraoxonase 1 |
increases expression multiple interactions |
ISO |
pitavastatin results in increased expression of PON1 mRNA farnesyl pyrophosphate inhibits the reaction [pitavastatin results in increased expression of PON1 mRNA]; Mevalonic Acid inhibits the reaction [pitavastatin results in increased expression of PON1 mRNA]; Plicamycin inhibits the reaction [pitavastatin results in increased expression of PON1 mRNA] |
CTD |
PMID:15690306 |
|
NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
increases expression multiple interactions |
ISO |
pitavastatin results in increased expression of PPARA mRNA pitavastatin promotes the reaction [Bezafibrate results in increased activity of [PPARA protein binds to RXRA protein]]; PPARA protein affects the reaction [pitavastatin results in increased expression of ABCA1 mRNA] |
CTD |
PMID:11779144 PMID:21554872 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
increases expression |
ISO |
pitavastatin results in increased expression of PPARD mRNA |
CTD |
PMID:21554872 |
|
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Rap1a |
RAP1A, member of RAS oncogene family |
decreases expression decreases prenylation |
ISO |
pitavastatin results in decreased expression of RAP1A protein alternative form pitavastatin results in decreased prenylation of RAP1A protein |
CTD |
PMID:37956312 |
|
NCBI chr 2:193,208,631...193,286,513
Ensembl chr 2:193,208,635...193,286,501
|
|
G |
Rxra |
retinoid X receptor alpha |
multiple interactions |
ISO |
pitavastatin promotes the reaction [Bezafibrate results in increased activity of [PPARA protein binds to RXRA protein]] |
CTD |
PMID:11779144 |
|
NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
affects transport |
ISO |
SLCO1A4 protein affects the transport of pitavastatin |
CTD |
PMID:19833843 |
|
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO |
pitavastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of STAT1 protein] |
CTD |
PMID:18323514 |
|
NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
pitavastatin inhibits the reaction [LEP gene mutant form results in increased expression of TNF mRNA]; pitavastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] |
CTD |
PMID:18323514 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions increases expression decreases expression |
EXP ISO |
[[colestimide co-treated with Pravastatin] results in increased expression of ABCA1 protein] which results in decreased abundance of Cholesterol; [colestimide co-treated with Pravastatin] affects the expression of ABCA1 mRNA; [colestimide co-treated with Pravastatin] affects the expression of ABCA1 protein cotreatment with pravastatin and colestimide increases expression of abca1 mRNA and protein in rat liver; and decreases expression of abca1 mRNA and protein in rat small intestine Pravastatin results in decreased expression of ABCA1 |
CTD RGD |
PMID:17526932 PMID:19461118 PMID:17526932 |
RGD:2308820 |
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions affects import |
ISO |
Pravastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid] ABCB11 protein affects the import of Pravastatin |
CTD |
PMID:15901796 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases transport |
ISO |
ABCB1 protein results in increased transport of Pravastatin; ABCB1 protein results in increased transport of Pravastatin analog |
CTD |
PMID:15616150 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
increases expression |
EXP |
Pravastatin results in increased expression of ABCB4 mRNA |
CTD |
PMID:15242490 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
affects export increases expression multiple interactions affects transport |
ISO EXP |
ABCC2 protein affects the export of Pravastatin Pravastatin results in increased expression of ABCC2 protein ABCC2 protein binds to and results in increased uptake of Pravastatin analog; Pravastatin analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein]; Pravastatin promotes the reaction [ABCC2 protein results in increased export of 5(6)-carboxy-2',7'-dichlorofluorescein] ABCC2 protein affects the transport of Pravastatin |
CTD |
PMID:15901800 PMID:15955871 PMID:23562342 PMID:24909372 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases expression |
EXP |
Pravastatin results in increased expression of ABCC3 protein |
CTD |
PMID:24909372 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
increases transport |
ISO |
ABCC4 protein results in increased transport of Pravastatin |
CTD |
PMID:17939016 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Abcd3 |
ATP binding cassette subfamily D member 3 |
decreases expression |
ISO |
Pravastatin results in decreased expression of ABCD3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:209,852,087...209,905,763
Ensembl chr 2:209,852,087...209,906,020
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
affects export increases activity |
ISO |
ABCG2 protein affects the export of Pravastatin Pravastatin results in increased activity of ABCG2 protein |
CTD |
PMID:15901800 PMID:27475308 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
increases expression |
EXP |
Pravastatin results in increased expression of ABCG5 mRNA |
CTD |
PMID:15242490 |
|
NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
increases expression |
EXP |
Pravastatin results in increased expression of ABCG8 mRNA |
CTD |
PMID:15242490 |
|
NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912
|
|
G |
Acaa1b |
acetyl-Coenzyme A acyltransferase 1B |
decreases expression |
ISO |
Pravastatin results in decreased expression of ACAA1B mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:118,872,996...118,881,852
Ensembl chr 8:118,872,997...118,881,825
|
|
G |
Acaa2 |
acetyl-CoA acyltransferase 2 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of ACAA2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr18:68,345,136...68,373,246
Ensembl chr18:68,345,012...68,373,249
|
|
G |
Acat1 |
acetyl-CoA acetyltransferase 1 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of ACAT1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:53,979,813...54,008,861
Ensembl chr 8:53,979,813...54,008,855
|
|
G |
Ace |
angiotensin I converting enzyme |
multiple interactions |
EXP |
[INS1 protein co-treated with Pravastatin] inhibits the reaction [Streptozocin results in increased expression of ACE protein] |
CTD |
PMID:29682576 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
multiple interactions |
EXP |
[INS1 protein co-treated with Pravastatin] inhibits the reaction [Streptozocin results in decreased expression of ACE2 protein] |
CTD |
PMID:29682576 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Acnat1 |
acyl-coenzyme A amino acid N-acyltransferase 1 |
decreases expression |
EXP |
Pravastatin results in decreased expression of ACNAT1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:63,796,651...63,801,601
Ensembl chr 5:63,764,666...63,786,144 Ensembl chr 5:63,764,666...63,786,144
|
|
G |
Acot1 |
acyl-CoA thioesterase 1 |
increases expression decreases expression |
EXP ISO |
Pravastatin results in increased expression of ACOT1 mRNA Pravastatin results in decreased expression of ACOT1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:103,636,173...103,644,167
Ensembl chr 6:103,636,041...103,644,163
|
|
G |
Acot12 |
acyl-CoA thioesterase 12 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of ACOT12 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:22,986,867...23,027,538
Ensembl chr 2:22,986,626...23,027,536
|
|
G |
Acot2 |
acyl-CoA thioesterase 2 |
affects expression |
ISO |
Pravastatin affects the expression of ACOT2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:103,611,738...103,619,404
Ensembl chr 6:103,611,544...103,619,245
|
|
G |
Acot3 |
acyl-CoA thioesterase 3 |
decreases expression |
ISO |
Pravastatin results in decreased expression of ACOT3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:103,682,518...103,688,735
Ensembl chr 6:103,682,596...103,688,427 Ensembl chr 6:103,682,596...103,688,427
|
|
G |
Acot4 |
acyl-CoA thioesterase 4 |
decreases expression |
ISO |
Pravastatin results in decreased expression of ACOT4 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:103,668,699...103,674,037
Ensembl chr 6:103,668,753...103,673,917
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of ACOX1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Acsf2 |
acyl-CoA synthetase family member 2 |
increases expression decreases expression |
EXP ISO |
Pravastatin results in increased expression of ACSF2 mRNA Pravastatin results in decreased expression of ACSF2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:79,504,510...79,546,714
Ensembl chr10:79,504,511...79,546,673
|
|
G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
decreases expression |
ISO |
Pravastatin results in decreased expression of ACSL1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541
|
|
G |
Acta1 |
actin, alpha 1, skeletal muscle |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of ACTA1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr19:51,883,709...51,886,735
Ensembl chr19:51,883,715...51,886,742
|
|
G |
Adamdec1 |
ADAM-like, decysin 1 |
increases expression |
ISO EXP |
Pravastatin results in increased expression of ADAMDEC1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr15:42,900,629...42,921,684
Ensembl chr15:42,900,636...42,921,712
|
|
G |
Adh1c |
alcohol dehydrogenase 1C (class I), gamma polypeptide |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of ADH1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892
|
|
G |
Adh7 |
alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of ADH7 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:226,748,724...226,763,183
Ensembl chr 2:226,741,788...226,763,182
|
|
G |
Agt |
angiotensinogen |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of AGT mRNA |
CTD |
PMID:27225895 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Aif1 |
allograft inflammatory factor 1 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of AIF1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of AKR1C18 mRNA Pravastatin results in decreased expression of AKR1C3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
Pravastatin inhibits the reaction [Carboplatin results in increased activity of and results in increased phosphorylation of AKT1 protein] [Pravastatin co-treated with olmesartan] results in increased phosphorylation of AKT1 protein; [resveratrol co-treated with Pravastatin] results in increased phosphorylation of AKT1 protein Pravastatin results in increased phosphorylation of AKT1 protein |
CTD |
PMID:17170375 PMID:17188708 PMID:18483861 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of ALDH1A1 mRNA |
CTD |
PMID:16763553 PMID:27225895 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldh1a2 |
aldehyde dehydrogenase 1 family, member A2 |
multiple interactions decreases expression |
ISO |
Cholesterol, Dietary inhibits the reaction [Pravastatin results in decreased expression of ALDH1A2 mRNA] |
CTD |
PMID:16763553 |
|
NCBI chr 8:71,877,850...71,957,107
Ensembl chr 8:71,877,850...71,957,107
|
|
G |
Aldh1a3 |
aldehyde dehydrogenase 1 family, member A3 |
affects expression |
EXP ISO |
Pravastatin affects the expression of ALDH1A3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:119,982,272...120,017,416
Ensembl chr 1:119,982,277...120,017,436
|
|
G |
Aldoart2 |
aldolase 1 A retrogene 2 |
increases expression decreases expression |
ISO EXP |
Pravastatin results in increased expression of ALDOART2 mRNA Pravastatin results in decreased expression of ALDOART2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:72,939,821...72,941,511
Ensembl chr 6:72,939,788...72,941,709
|
|
G |
Ampd3 |
adenosine monophosphate deaminase 3 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of AMPD3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:164,884,823...164,929,899
Ensembl chr 1:164,885,320...164,929,887
|
|
G |
Angptl3 |
angiopoietin-like 3 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of ANGPTL3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:113,703,007...113,710,044
Ensembl chr 5:113,703,012...113,709,957
|
|
G |
Ank2 |
ankyrin 2 |
increases expression decreases expression |
EXP ISO |
Pravastatin results in increased expression of ANK2 mRNA Pravastatin results in decreased expression of ANK2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:215,378,028...215,954,015
Ensembl chr 2:215,379,680...215,862,923
|
|
G |
Anks6 |
ankyrin repeat and sterile alpha motif domain containing 6 |
increases expression decreases expression |
EXP ISO |
Pravastatin results in increased expression of ANKS6 mRNA Pravastatin results in decreased expression of ANKS6 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:61,309,183...61,350,596
Ensembl chr 5:61,309,183...61,350,596
|
|
G |
Apoa1 |
apolipoprotein A1 |
increases expression decreases expression |
EXP ISO |
Pravastatin results in increased expression of APOA1 mRNA Pravastatin results in decreased expression of APOA1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
App |
amyloid beta precursor protein |
increases expression |
ISO |
Pravastatin results in increased expression of APP |
CTD |
PMID:19461118 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Arg2 |
arginase 2 |
increases expression |
ISO |
Pravastatin results in increased expression of ARG2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:97,936,002...97,961,379
Ensembl chr 6:97,936,002...97,961,378
|
|
G |
Arhgap11a |
Rho GTPase activating protein 11A |
decreases expression affects expression |
EXP ISO |
Pravastatin results in decreased expression of ARHGAP11A mRNA Pravastatin affects the expression of ARHGAP11A mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:100,590,865...100,607,146
Ensembl chr 3:100,590,865...100,607,559
|
|
G |
Arrdc3 |
arrestin domain containing 3 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of ARRDC3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:11,137,464...11,149,978
Ensembl chr 2:11,137,460...11,149,978
|
|
G |
Atp4a |
ATPase H+/K+ transporting subunit alpha |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of ATP4A mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:85,961,607...85,974,972
Ensembl chr 1:85,961,708...85,974,844
|
|
G |
Atp6v0d2 |
ATPase H+ transporting V0 subunit D2 |
increases expression decreases expression |
EXP ISO |
Pravastatin results in increased expression of ATP6V0D2 mRNA Pravastatin results in decreased expression of ATP6V0D2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:33,336,257...33,385,354
Ensembl chr 5:33,336,264...33,385,354
|
|
G |
Axin2 |
axin 2 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of AXIN2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:93,893,830...93,927,042
Ensembl chr10:93,899,245...93,926,231
|
|
G |
Bard1 |
BRCA1 associated RING domain 1 |
decreases expression affects expression |
EXP ISO |
Pravastatin results in decreased expression of BARD1 mRNA Pravastatin affects the expression of BARD1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 9:72,616,070...72,694,553
Ensembl chr 9:72,623,155...72,694,265
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
[LDLR gene mutant form results in increased susceptibility to Pravastatin] which affects the expression of BAX protein |
CTD |
PMID:26875785 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
[LDLR gene mutant form results in increased susceptibility to Pravastatin] which affects the expression of BCL2 protein |
CTD |
PMID:26875785 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bhlha15 |
basic helix-loop-helix family, member a15 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of BHLHA15 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr12:10,420,465...10,424,641
Ensembl chr12:10,420,467...10,424,713
|
|
G |
Bmal2 |
basic helix-loop-helix ARNT like 2 |
affects expression increases expression |
EXP ISO |
Pravastatin affects the expression of BMAL2 mRNA Pravastatin results in increased expression of BMAL2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:179,699,432...179,747,710
Ensembl chr 4:179,699,502...179,746,949
|
|
G |
Bmper |
BMP-binding endothelial regulator |
affects expression increases expression |
EXP ISO |
Pravastatin affects the expression of BMPER mRNA Pravastatin results in increased expression of BMPER mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:21,732,225...21,977,261
Ensembl chr 8:21,732,225...21,977,256
|
|
G |
Bub1b |
BUB1 mitotic checkpoint serine/threonine kinase B |
affects expression decreases expression |
ISO EXP |
Pravastatin affects the expression of BUB1B mRNA Pravastatin results in decreased expression of BUB1B mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:105,563,089...105,615,547
Ensembl chr 3:105,563,138...105,615,547
|
|
G |
C1qb |
complement C1q B chain |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of C1QB mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:149,118,843...149,124,394
Ensembl chr 5:149,118,846...149,124,407
|
|
G |
C1qc |
complement C1q C chain |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of C1QC mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:149,127,412...149,130,757
Ensembl chr 5:149,127,415...149,131,017
|
|
G |
C5ar1 |
complement C5a receptor 1 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of C5AR1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:76,948,622...76,959,826
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage |
ISO EXP |
[LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in increased cleavage of CASP3 protein; Pravastatin inhibits the reaction [Carboplatin results in increased expression of CASP3 protein] Pravastatin results in increased cleavage of CASP3 protein Pravastatin inhibits the reaction [Carboplatin results in increased expression of CASP3 protein]; Pravastatin inhibits the reaction [Cisplatin results in increased expression of CASP3 protein] |
CTD |
PMID:18483861 PMID:20368269 PMID:26875785 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP |
Pravastatin inhibits the reaction [Carboplatin results in increased expression of CASP9 protein] |
CTD |
PMID:18483861 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
increases activity |
ISO |
Pravastatin results in increased activity of CAT protein |
CTD |
PMID:17479860 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl12 |
C-C motif chemokine ligand 12 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of CCL12 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:67,070,230...67,071,780
Ensembl chr10:67,070,230...67,071,780
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
Pravastatin inhibits the reaction [LEP gene mutant form results in increased expression of CCL2 mRNA]; Pravastatin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA] Pravastatin inhibits the reaction [lopinavir-ritonavir drug combination results in increased secretion of CCL2 protein]; Pravastatin inhibits the reaction [Ritonavir results in increased secretion of CCL2 protein] |
CTD |
PMID:18323514 PMID:20884875 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl9 |
C-C motif chemokine ligand 9 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of CCL6 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:68,366,486...68,371,408
Ensembl chr10:68,366,487...68,371,369
|
|
G |
Cd209d |
CD209d molecule |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of CD209 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr12:1,891,109...1,897,559
Ensembl chr12:1,891,113...1,901,171
|
|
G |
Cd28 |
Cd28 molecule |
decreases expression affects expression |
ISO EXP |
Pravastatin results in decreased expression of CD28 mRNA Pravastatin affects the expression of CD28 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 9:62,166,324...62,194,674
Ensembl chr 9:62,166,192...62,194,685
|
|
G |
Cd40 |
CD40 molecule |
affects expression |
EXP ISO |
Pravastatin affects the expression of CD40 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
|
|
G |
Cd7 |
Cd7 molecule |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of CD7 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:106,304,046...106,306,963
Ensembl chr10:106,304,056...106,306,967
|
|
G |
Cdc27 |
cell division cycle 27 |
affects expression increases expression |
EXP ISO |
Pravastatin affects the expression of CDC27 mRNA Pravastatin results in increased expression of CDC27 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:89,400,720...89,449,816
Ensembl chr10:89,400,940...89,449,736
|
|
G |
Cdc6 |
cell division cycle 6 |
decreases expression affects expression |
EXP ISO |
Pravastatin results in decreased expression of CDC6 mRNA Pravastatin affects the expression of CDC6 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:83,864,189...83,878,011
Ensembl chr10:83,864,638...83,878,011
|
|
G |
Cdca7l |
cell division cycle associated 7 like |
affects expression decreases expression |
ISO EXP |
Pravastatin affects the expression of CDCA7L mRNA Pravastatin results in decreased expression of CDCA7L mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:138,793,953...138,839,889
Ensembl chr 6:138,794,228...138,839,888
|
|
G |
Cdhr5 |
cadherin-related family member 5 |
decreases expression increases expression |
ISO EXP |
Pravastatin results in decreased expression of CDHR5 mRNA Pravastatin results in increased expression of CDHR5 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:196,373,110...196,381,609
Ensembl chr 1:196,373,112...196,381,543
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
Pravastatin inhibits the reaction [Benzo(a)pyrene results in decreased degradation of CDKN1A protein]; Pravastatin inhibits the reaction [Fluorouracil results in decreased degradation of CDKN1A protein] |
CTD |
PMID:15625077 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cds1 |
CDP-diacylglycerol synthase 1 |
increases expression |
ISO EXP |
Pravastatin results in increased expression of CDS1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr14:7,820,328...7,882,943
Ensembl chr14:7,820,351...7,882,681
|
|
G |
Cebpd |
CCAAT/enhancer binding protein delta |
increases expression |
ISO |
Pravastatin results in increased expression of CEBPD mRNA |
CTD |
PMID:27225895 |
|
NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829
|
|
G |
Cers6 |
ceramide synthase 6 |
decreases expression |
ISO |
Pravastatin results in decreased expression of CERS6 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:53,630,637...53,879,692
Ensembl chr 3:53,630,959...53,876,848
|
|
G |
Cesl1 |
carboxylesterase-like 1 |
decreases expression |
EXP |
Pravastatin results in decreased expression of CESL1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr19:22,670,709...23,006,329
Ensembl chr19:22,670,712...22,712,608
|
|
G |
Cfap96 |
cilia and flagella associated protein 96 |
increases expression |
EXP |
Pravastatin results in increased expression of CFAP96 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr16:46,291,075...46,315,616
Ensembl chr16:46,291,311...46,315,625
|
|
G |
Cip2a |
cellular inhibitor of PP2A |
decreases expression |
EXP |
Pravastatin results in decreased expression of CIP2A mRNA |
CTD |
PMID:27225895 |
|
NCBI chr11:51,792,143...51,823,016
Ensembl chr11:51,795,024...51,822,938
|
|
G |
Cited1 |
Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 1 |
decreases expression increases expression |
ISO EXP |
Pravastatin results in decreased expression of CITED1 mRNA Pravastatin results in increased expression of CITED1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr X:67,350,376...67,355,072
Ensembl chr X:67,350,373...67,355,162
|
|
G |
Clcn6 |
chloride voltage-gated channel 6 |
increases expression |
ISO EXP |
Pravastatin results in increased expression of CLCN6 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:158,434,299...158,465,174
Ensembl chr 5:158,434,299...158,465,059
|
|
G |
Clec4f |
C-type lectin domain family 4, member F |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of CLEC4F mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:116,129,023...116,138,744
Ensembl chr 4:116,129,023...116,138,775
|
|
G |
Clstn3 |
calsyntenin 3 |
decreases expression affects expression |
ISO EXP |
Pravastatin results in decreased expression of CLSTN3 mRNA Pravastatin affects the expression of CLSTN3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:157,331,494...157,364,769
Ensembl chr 4:157,331,494...157,364,769
|
|
G |
Cnn1 |
calponin 1 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of CNN1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:20,632,434...20,641,097
Ensembl chr 8:20,632,338...20,641,098
|
|
G |
Cpt1b |
carnitine palmitoyltransferase 1B |
decreases expression affects expression |
ISO EXP |
Pravastatin results in decreased expression of CPT1B mRNA Pravastatin affects the expression of CPT1B mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:120,491,354...120,500,833
Ensembl chr 7:120,491,354...120,500,404
|
|
G |
Cpt2 |
carnitine palmitoyltransferase 2 |
decreases expression |
ISO |
Pravastatin results in decreased expression of CPT2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095
|
|
G |
Crat |
carnitine O-acetyltransferase |
increases expression affects expression |
EXP ISO |
Pravastatin results in increased expression of CRAT mRNA Pravastatin affects the expression of CRAT mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:13,675,684...13,689,282
Ensembl chr 3:13,675,684...13,689,255
|
|
G |
Creb3l3 |
cAMP responsive element binding protein 3-like 3 |
decreases expression affects expression |
ISO EXP |
Pravastatin results in decreased expression of CREB3L3 mRNA Pravastatin affects the expression of CREB3L3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:8,622,614...8,631,053
Ensembl chr 7:8,622,614...8,631,048
|
|
G |
Crp |
C-reactive protein |
decreases expression increases expression |
ISO EXP |
Pravastatin results in decreased expression of CRP mRNA Pravastatin results in increased expression of CRP mRNA |
CTD |
PMID:27225895 |
|
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Csad |
cysteine sulfinic acid decarboxylase |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of CSAD mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:133,308,571...133,337,914
Ensembl chr 7:133,308,574...133,337,615
|
|
G |
Csf1r |
colony stimulating factor 1 receptor |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of CSF1R mRNA |
CTD |
PMID:27225895 |
|
NCBI chr18:54,546,673...54,590,418
Ensembl chr18:54,546,659...54,590,415
|
|
G |
Csmd1 |
CUB and Sushi multiple domains 1 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of CSMD1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr16:72,218,189...73,818,380
Ensembl chr16:72,218,503...73,817,614
|
|
G |
Ctnnb1 |
catenin beta 1 |
affects localization multiple interactions |
EXP |
Pravastatin affects the localization of CTNNB1 protein [resveratrol co-treated with Pravastatin] affects the localization of CTNNB1 protein |
CTD |
PMID:17188708 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
affects expression increases expression |
EXP ISO |
Pravastatin affects the expression of CXCL2 mRNA Pravastatin results in increased expression of CXCL2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
decreases expression |
EXP |
Pravastatin results in decreased expression of CYBA protein |
CTD |
PMID:17170375 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
EXP |
Pravastatin inhibits the reaction [Carboplatin results in increased expression of CYCS protein] |
CTD |
PMID:18483861 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of CYP1A2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
affects expression increases expression |
EXP ISO |
Pravastatin affects the expression of CYP1B1 mRNA Pravastatin results in increased expression of CYP1B1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2b21 |
cytochrome P450, family 2, subfamily b, polypeptide 21 |
decreases expression |
EXP |
Pravastatin results in decreased expression of CYP2B21 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:81,886,097...81,915,066
Ensembl chr 1:81,886,098...81,915,066
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
affects expression |
ISO |
Pravastatin affects the expression of CYP2B10 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2d3 |
cytochrome P450, family 2, subfamily d, polypeptide 3 |
decreases expression |
EXP |
Pravastatin results in decreased expression of CYP2D3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:113,917,711...113,922,068
Ensembl chr 7:113,908,947...113,922,084
|
|
G |
Cyp2j4 |
cytochrome P450, family 2, subfamily j, polypeptide 4 |
decreases expression |
EXP |
Pravastatin results in decreased expression of CYP2J4 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:111,179,981...111,207,490
Ensembl chr 5:111,178,703...111,244,794
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
decreases expression |
EXP |
Pravastatin results in decreased expression of CYP3A23-3A1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
|
|
G |
Cyp4a1 |
cytochrome P450, family 4, subfamily a, polypeptide 1 |
decreases expression |
EXP |
Pravastatin results in decreased expression of CYP4A1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:129,123,323...129,137,464
Ensembl chr 5:129,123,336...129,137,464
|
|
G |
Cyp4a2 |
cytochrome P450, family 4, subfamily a, polypeptide 2 |
affects expression |
EXP |
Pravastatin affects the expression of CYP4A2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:128,922,355...128,934,188
Ensembl chr 5:128,923,615...128,934,165
|
|
G |
Cyp4a3 |
cytochrome P450, family 4, subfamily a, polypeptide 3 |
decreases expression |
EXP |
Pravastatin results in decreased expression of CYP4A3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:129,097,571...129,115,488
Ensembl chr 5:129,097,926...129,115,463
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of CYP51 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410
|
|
G |
Decr1 |
2,4-dienoyl-CoA reductase 1 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of DECR1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:29,411,172...29,439,054
Ensembl chr 5:29,411,172...29,439,018
|
|
G |
Depdc1b |
DEP domain containing 1B |
decreases expression affects expression |
EXP ISO |
Pravastatin results in decreased expression of DEPDC1B mRNA Pravastatin affects the expression of DEPDC1B mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:39,891,163...39,963,779
Ensembl chr 2:39,891,481...39,963,779
|
|
G |
Derl3 |
derlin 3 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of DERL3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr20:12,754,490...12,768,454
Ensembl chr20:12,763,543...12,767,027
|
|
G |
Dio3 |
iodothyronine deiodinase 3 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of DIO3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660
|
|
G |
Dlgap1 |
DLG associated protein 1 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of DLGAP1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 9:109,857,500...110,726,817
Ensembl chr 9:110,167,448...110,726,817
|
|
G |
Dnaja1 |
DnaJ heat shock protein family (Hsp40) member A1 |
affects farnesylation |
ISO |
Pravastatin affects the farnesylation of DNAJA1 protein |
CTD |
PMID:20884875 |
|
NCBI chr 5:55,842,414...55,853,326
Ensembl chr 5:55,842,426...55,853,967
|
|
G |
Dnase2b |
deoxyribonuclease 2 beta |
increases expression decreases expression |
EXP ISO |
Pravastatin results in increased expression of DNASE2B mRNA Pravastatin results in decreased expression of DNASE2B mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:235,470,915...235,515,211
Ensembl chr 2:235,470,919...235,486,295
|
|
G |
Dpysl2 |
dihydropyrimidinase-like 2 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of DPYSL2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr15:41,005,551...41,111,724
Ensembl chr15:41,005,551...41,111,829
|
|
G |
Dtl |
denticleless E3 ubiquitin protein ligase homolog |
decreases expression affects expression |
EXP ISO |
Pravastatin results in decreased expression of DTL mRNA Pravastatin affects the expression of DTL mRNA |
CTD |
PMID:27225895 |
|
NCBI chr13:103,115,810...103,155,029
Ensembl chr13:103,117,186...103,154,890
|
|
G |
Ech1 |
enoyl-CoA hydratase 1 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of ECH1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:84,114,494...84,120,788
Ensembl chr 1:84,112,751...84,120,795
|
|
G |
Edn1 |
endothelin 1 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of EDN1 protein Pravastatin results in decreased expression of EDN1 mRNA; Pravastatin results in decreased expression of EDN1 protein |
CTD |
PMID:12105140 PMID:19812503 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Efhb |
EF hand domain family, member B |
increases expression |
ISO EXP |
Pravastatin results in increased expression of EFHB mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 9:6,372,191...6,441,678
Ensembl chr 9:6,372,194...6,441,919
|
|
G |
Ehhadh |
enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of EHHADH mRNA |
CTD |
PMID:27225895 |
|
NCBI chr11:79,241,927...79,275,173
Ensembl chr11:79,241,938...79,275,188
|
|
G |
Enpp5 |
ectonucleotide pyrophosphatase/phosphodiesterase family member 5 |
affects expression decreases expression |
EXP ISO |
Pravastatin affects the expression of ENPP5 mRNA Pravastatin results in decreased expression of ENPP5 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 9:16,910,187...16,917,633
Ensembl chr 9:16,910,831...16,917,480
|
|
G |
Entpd2 |
ectonucleoside triphosphate diphosphohydrolase 2 |
decreases expression increases expression |
ISO EXP |
Pravastatin results in decreased expression of ENTPD2 mRNA Pravastatin results in increased expression of ENTPD2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:8,213,575...8,219,094
Ensembl chr 3:8,213,663...8,226,866
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of EPHX2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615
|
|
G |
Ephx4 |
epoxide hydrolase 4 |
increases expression affects expression |
EXP ISO |
Pravastatin results in increased expression of EPHX4 mRNA Pravastatin affects the expression of EPHX4 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr14:2,343,376...2,372,680
Ensembl chr14:2,340,248...2,373,022
|
|
G |
Evi2a |
ecotropic viral integration site 2A |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of EVI2A mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:64,485,760...64,489,660
Ensembl chr10:64,485,200...64,489,843
|
|
G |
F13a1 |
coagulation factor XIII A1 chain |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of F13A1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr17:27,815,723...27,992,494
Ensembl chr17:27,815,702...27,992,700
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
decreases expression |
ISO |
Pravastatin results in decreased expression of FABP1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
|
|
G |
Fabp2 |
fatty acid binding protein 2 |
increases expression decreases expression |
EXP ISO |
Pravastatin results in increased expression of FABP2 mRNA Pravastatin results in decreased expression of FABP2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:211,040,032...211,044,089
Ensembl chr 2:211,040,032...211,044,089
|
|
G |
Fabp5 |
fatty acid binding protein 5 |
increases expression |
ISO EXP |
Pravastatin results in increased expression of FABP5 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:91,765,056...91,768,716
Ensembl chr 2:91,765,056...91,853,773
|
|
G |
Far1 |
fatty acyl CoA reductase 1 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of FAR1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:167,644,622...167,705,868
Ensembl chr 1:167,644,677...167,705,730
|
|
G |
Fbn1 |
fibrillin 1 |
increases expression |
ISO |
Pravastatin results in increased expression of FBN1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:112,554,257...112,750,835
Ensembl chr 3:112,554,925...112,750,889
|
|
G |
Fbp2 |
fructose-bisphosphatase 2 |
affects expression |
EXP |
Pravastatin affects the expression of FBP2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr17:2,236,088...2,253,702
Ensembl chr17:2,236,336...2,253,698
|
|
G |
Fdft1 |
farnesyl diphosphate farnesyl transferase 1 |
affects activity |
ISO |
Pravastatin affects the activity of FDFT1 protein |
CTD |
PMID:8517861 |
|
NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287
|
|
G |
Fgd2 |
FYVE, RhoGEF and PH domain containing 2 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of FGD2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr20:7,424,795...7,441,603
Ensembl chr20:7,424,790...7,441,603
|
|
G |
Fgf13 |
fibroblast growth factor 13 |
affects expression increases expression |
EXP ISO |
Pravastatin affects the expression of FGF13 mRNA Pravastatin results in increased expression of FGF13 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr X:137,276,498...137,800,056
Ensembl chr X:137,276,511...137,800,391
|
|
G |
Flacc1 |
flagellum associated containing coiled-coil domains 1 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of FLACC1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 9:60,315,581...60,343,692
Ensembl chr 9:60,315,582...60,343,648
|
|
G |
Flot1 |
flotillin 1 |
decreases expression |
ISO |
Pravastatin results in decreased expression of FLOT1 protein |
CTD |
PMID:12628479 |
|
NCBI chr20:2,917,864...2,927,993
Ensembl chr20:2,917,137...2,927,978
|
|
G |
Folr2 |
folate receptor beta |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of FOLR2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:156,200,044...156,218,380
Ensembl chr 1:156,200,060...156,205,724
|
|
G |
Foxo1 |
forkhead box O1 |
decreases phosphorylation |
ISO |
Pravastatin results in decreased phosphorylation of FOXO1 protein |
CTD |
PMID:33034787 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Gck |
glucokinase |
decreases expression |
EXP |
Pravastatin results in decreased expression of GCK mRNA |
CTD |
PMID:27225895 |
|
NCBI chr14:80,785,060...80,829,842
Ensembl chr14:80,785,060...80,826,995
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression decreases expression |
ISO EXP |
Pravastatin results in increased expression of GCLC mRNA Pravastatin results in decreased expression of GCLC mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gcnt2 |
glucosaminyl (N-acetyl) transferase 2 |
increases expression decreases expression |
ISO EXP |
Pravastatin results in increased expression of GCNT2 mRNA Pravastatin results in decreased expression of GCNT2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr17:23,796,859...23,901,625
Ensembl chr17:23,796,859...23,901,611
|
|
G |
Glb1 |
galactosidase, beta 1 |
multiple interactions |
ISO |
Pravastatin inhibits the reaction [lopinavir-ritonavir drug combination results in increased activity of GLB1 protein]; Pravastatin inhibits the reaction [Ritonavir results in increased activity of GLB1 protein] |
CTD |
PMID:20884875 |
|
NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127
|
|
G |
Gldc |
glycine decarboxylase |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of GLDC mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:227,883,249...227,962,119
Ensembl chr 1:227,883,249...227,962,097
|
|
G |
Gls2 |
glutaminase 2 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of GLS2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:617,252...633,424
Ensembl chr 7:617,288...633,426
|
|
G |
Gpr85 |
G protein-coupled receptor 85 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of GPR85 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:42,100,138...42,109,584
Ensembl chr 4:42,102,941...42,109,566
|
|
G |
Gstk1 |
glutathione S-transferase kappa 1 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of GSTK1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:71,118,979...71,123,298
Ensembl chr 4:71,118,896...71,123,292
|
|
G |
Hadh |
hydroxyacyl-CoA dehydrogenase |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of HADH mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:219,787,935...219,830,335
Ensembl chr 2:219,787,927...219,830,353
|
|
G |
Hadha |
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of HADHA mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:26,187,969...26,227,605
Ensembl chr 6:26,187,956...26,227,869
|
|
G |
Hadhb |
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of HADHB mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:26,153,572...26,187,668
Ensembl chr 6:26,153,578...26,184,869
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
increases expression |
EXP ISO |
Pravastatin results in increased expression of HAMP mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:86,170,926...86,172,865
Ensembl chr 1:86,170,901...86,172,891
|
|
G |
Hax1 |
HCLS1 associated protein X-1 |
multiple interactions |
EXP |
Pravastatin inhibits the reaction [Carboplatin results in decreased expression of HAX1 protein] |
CTD |
PMID:18483861 |
|
NCBI chr 2:175,434,242...175,437,926
Ensembl chr 2:175,434,238...175,437,714
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
decreases response to substance increases expression decreases activity affects expression |
ISO EXP |
HMGCR gene SNP results in decreased susceptibility to Pravastatin Pravastatin results in increased expression of HMGCR mRNA Pravastatin results in decreased activity of HMGCR protein Pravastatin affects the expression of HMGCR mRNA |
CTD |
PMID:8517861 PMID:8593127 PMID:15199031 PMID:27225895 PMID:29969672 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
increases expression |
ISO |
Pravastatin results in increased expression of HMGCS1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
EXP ISO |
[[Pravastatin co-treated with pirinixic acid] co-treated with [RXRA protein co-treated with PPARA protein]] results in increased expression of HMOX1 mRNA; [Pravastatin co-treated with [RXRA protein co-treated with PPARA protein]] results in increased expression of HMOX1 mRNA; [Pravastatin co-treated with pirinixic acid] results in increased expression of HMOX1 mRNA; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Pravastatin results in increased expression of HMOX1 protein]; Pravastatin promotes the reaction [PPARA protein binds to HMOX1 promoter] |
CTD |
PMID:20368269 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hopx |
HOP homeobox |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of HOPX mRNA |
CTD |
PMID:27225895 |
|
NCBI chr14:31,055,912...31,082,909
Ensembl chr14:31,075,148...31,082,909
|
|
G |
Hrg |
histidine-rich glycoprotein |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of HRG mRNA |
CTD |
PMID:27225895 |
|
NCBI chr11:78,054,488...78,069,402
Ensembl chr11:78,054,498...78,069,389
|
|
G |
Hsd17b7 |
hydroxysteroid (17-beta) dehydrogenase 7 |
increases expression |
ISO EXP |
Pravastatin results in increased expression of HSD17B7 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr13:82,170,079...82,190,018
Ensembl chr13:82,173,179...82,190,017
|
|
G |
Hsdl2 |
hydroxysteroid dehydrogenase like 2 |
decreases expression increases expression |
ISO EXP |
Pravastatin results in decreased expression of HSDL2 mRNA Pravastatin results in increased expression of HSDL2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:74,443,933...74,479,104
Ensembl chr 5:74,443,872...74,479,839
|
|
G |
Idi1 |
isopentenyl-diphosphate delta isomerase 1 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of IDI1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr17:61,629,592...61,637,357
Ensembl chr17:61,629,594...61,637,357
|
|
G |
Ifnb1 |
interferon beta 1 |
multiple interactions |
ISO |
Pravastatin inhibits the reaction [Lipopolysaccharides results in increased expression of IFNB1 mRNA]; Pravastatin inhibits the reaction [Palmitic Acid results in increased expression of IFNB1 mRNA]; Pravastatin inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA] |
CTD |
PMID:18323514 |
|
NCBI chr 5:103,020,758...103,021,595
Ensembl chr 5:103,020,969...103,021,523
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression increases expression |
EXP ISO |
Pravastatin results in decreased expression of IL1B mRNA Pravastatin results in increased expression of IL1B mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions decreases expression |
ISO |
Pravastatin inhibits the reaction [LEP gene mutant form results in increased expression of IL6 mRNA]; Pravastatin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Pravastatin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Pravastatin inhibits the reaction [Palmitic Acid results in increased expression of IL6 mRNA]; Pravastatin inhibits the reaction [Poly I-C results in increased expression of IL6 mRNA]; Pravastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein] Pravastatin inhibits the reaction [lopinavir-ritonavir drug combination results in increased secretion of IL6 protein]; Pravastatin inhibits the reaction [Ritonavir results in increased secretion of IL6 protein] Pravastatin results in decreased expression of IL6 protein |
CTD |
PMID:17729120 PMID:18323514 PMID:19330073 PMID:20884875 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions increases response to substance |
EXP ISO |
[INS1 protein co-treated with Pravastatin] inhibits the reaction [Streptozocin results in decreased expression of ACE2 protein]; [INS1 protein co-treated with Pravastatin] inhibits the reaction [Streptozocin results in increased expression of ACE protein] [LDLR gene mutant form results in increased susceptibility to Pravastatin] inhibits the reaction [Glucose results in increased secretion of INS1 protein]; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of INS1 protein [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in increased susceptibility to INS1 protein |
CTD |
PMID:26875785 PMID:29682576 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Irf3 |
interferon regulatory factor 3 |
multiple interactions |
ISO |
Pravastatin inhibits the reaction [Palmitic Acid results in increased phosphorylation of IRF3 protein] |
CTD |
PMID:18323514 |
|
NCBI chr 1:95,479,966...95,484,926
Ensembl chr 1:95,479,821...95,484,935
|
|
G |
Itga2 |
integrin subunit alpha 2 |
multiple interactions |
EXP ISO |
geranylgeraniol inhibits the reaction [Pravastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]]; Mevalonic Acid inhibits the reaction [Pravastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]]; Pravastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein] |
CTD |
PMID:12500026 |
|
NCBI chr 2:46,520,345...46,621,487
Ensembl chr 2:46,523,948...46,621,481
|
|
G |
Itgb1 |
integrin subunit beta 1 |
multiple interactions |
EXP ISO |
geranylgeraniol inhibits the reaction [Pravastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]]; Mevalonic Acid inhibits the reaction [Pravastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]]; Pravastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein] |
CTD |
PMID:12500026 |
|
NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195
|
|
G |
Itgb6 |
integrin subunit beta 6 |
affects expression |
ISO |
Pravastatin affects the expression of ITGB6 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:45,046,295...45,170,532
Ensembl chr 3:45,048,044...45,121,671
|
|
G |
Kcns3 |
potassium voltage-gated channel, modifier subfamily S, member 3 |
increases expression |
ISO EXP |
Pravastatin results in increased expression of KCNS3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:33,808,314...33,865,018
Ensembl chr 6:33,808,216...33,865,125
|
|
G |
Kctd12 |
potassium channel tetramerization domain containing 12 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of KCTD12 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr15:79,800,078...79,806,017
Ensembl chr15:79,801,191...79,806,282
|
|
G |
Kif20a |
kinesin family member 20A |
affects expression decreases expression |
ISO EXP |
Pravastatin affects the expression of KIF20A mRNA Pravastatin results in decreased expression of KIF20A mRNA |
CTD |
PMID:27225895 |
|
NCBI chr18:26,230,294...26,238,780
Ensembl chr18:26,230,230...26,238,780
|
|
G |
Kif20b |
kinesin family member 20B |
affects expression decreases expression |
ISO EXP |
Pravastatin affects the expression of KIF20B mRNA Pravastatin results in decreased expression of KIF20B mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:232,428,293...232,483,798
Ensembl chr 1:232,428,371...232,483,787
|
|
G |
Kif23 |
kinesin family member 23 |
affects expression decreases expression |
ISO EXP |
Pravastatin affects the expression of KIF23 mRNA Pravastatin results in decreased expression of KIF23 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:62,397,908...62,425,162
Ensembl chr 8:62,397,948...62,425,072
|
|
G |
Kitlg |
KIT ligand |
increases expression affects expression |
EXP ISO |
Pravastatin results in increased expression of KITLG mRNA Pravastatin affects the expression of KITL mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214
|
|
G |
Klb |
klotho beta |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of KLB mRNA |
CTD |
PMID:27225895 |
|
NCBI chr14:42,899,050...42,950,788
Ensembl chr14:42,899,510...42,950,799
|
|
G |
Krt23 |
keratin 23 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of KRT23 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:84,434,445...84,450,773
Ensembl chr10:84,434,380...84,450,983
|
|
G |
Ldlr |
low density lipoprotein receptor |
increases activity increases response to substance multiple interactions |
ISO |
Pravastatin results in increased activity of LDLR protein [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in increased susceptibility to INS1 protein; LDLR gene mutant form results in increased susceptibility to Pravastatin [LDLR gene mutant form results in increased susceptibility to Pravastatin] inhibits the reaction [Glucose results in increased secretion of INS1 protein]; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which affects the expression of BAX protein; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which affects the expression of BCL2 protein; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of INS1 protein; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of SNAP25 protein; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of STX1A protein; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of VAMP2 protein; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in increased cleavage of CASP3 protein |
CTD |
PMID:8593127 PMID:26875785 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
Pravastatin inhibits the reaction [LEP gene mutant form results in increased expression of CCL2 mRNA]; Pravastatin inhibits the reaction [LEP gene mutant form results in increased expression of IL6 mRNA]; Pravastatin inhibits the reaction [LEP gene mutant form results in increased expression of TNF mRNA] |
CTD |
PMID:18323514 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lgals4 |
galectin 4 |
increases expression decreases expression |
EXP ISO |
Pravastatin results in increased expression of LGALS4 mRNA Pravastatin results in decreased expression of LGALS4 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:84,124,766...84,132,481
Ensembl chr 1:84,124,764...84,132,481
|
|
G |
Lgi2 |
leucine-rich repeat LGI family, member 2 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of LGI2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr14:58,415,965...58,443,450
Ensembl chr14:58,415,965...58,443,407
|
|
G |
Lmna |
lamin A/C |
increases expression |
ISO |
Pravastatin results in increased expression of LMNA protein |
CTD |
PMID:20884875 |
|
NCBI chr 2:173,939,751...173,960,423
Ensembl chr 2:173,939,751...173,960,423
|
|
G |
Lpl |
lipoprotein lipase |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of LPL mRNA |
CTD |
PMID:27225895 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Lrmda |
leucine rich melanocyte differentiation associated |
decreases expression |
ISO |
Pravastatin results in decreased expression of LRMDA mRNA |
CTD |
PMID:27225895 |
|
NCBI chr15:1,223,098...2,284,764
Ensembl chr15:1,225,710...2,284,749
|
|
G |
Lss |
lanosterol synthase |
increases expression |
EXP ISO |